

MEDICIS PHARMACEUTICAL CORP

Form 10-Q

November 09, 2006

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549  
FORM 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 30, 2006**

**OR**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission file number 0-18443**

**MEDICIS PHARMACEUTICAL CORPORATION**  
(Exact name of Registrant as specified in its charter)

Delaware

52-1574808

(State or other jurisdiction of  
incorporation or organization)

(I.R.S. Employer Identification No.)

8125 North Hayden Road  
Scottsdale, Arizona 85258-2463  
(Address of principal executive offices)  
(602) 808-8800

(Registrant's telephone number,  
including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):  
Large accelerated filer  Accelerated filer  Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2) YES  NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding at November 3, 2006
Class A Common Stock \$.014 Par Value	55,021,893

**MEDICIS PHARMACEUTICAL CORPORATION**  
**Table of Contents**

	Page
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
<b><u>Item 1 Financial Statements</u></b>	
<u>Condensed Consolidated Balance Sheets as of September 30, 2006 and December 31, 2005</u>	3
<u>Condensed Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2006 and 2005</u>	5
<u>Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2006 and 2005</u>	6
<u>Notes to the Condensed Consolidated Financial Statements</u>	7
<b><u>Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	20
<b><u>Item 3 Quantitative and Qualitative Disclosures About Market Risk</u></b>	42
<b><u>Item 4 Controls and Procedures</u></b>	42
<b><u>PART II. OTHER INFORMATION</u></b>	
<b><u>Item 1 Legal Proceedings</u></b>	43
<b><u>Item 1A Risk Factors</u></b>	44
<b><u>Item 6 Exhibits</u></b>	45
<b><u>SIGNATURES</u></b>	46
<u>EX-10.1</u>	
<u>EX-12</u>	
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32.1</u>	

**Table of Contents****Part I. Financial Information****Item 1. Financial Statements**

**MEDICIS PHARMACEUTICAL CORPORATION**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(in thousands, except share amounts)

	September 30, 2006 (unaudited)	December 31, 2005
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 107,777	\$ 446,997
Short-term investments	470,492	295,535
Accounts receivable, net	20,972	46,697
Inventories, net	20,084	19,076
Deferred tax assets, net	16,698	12,738
Other current assets	17,632	12,241
Total current assets	653,655	833,284
Property and equipment, net	6,438	5,416
Intangible assets:		
Intangible assets related to product line acquisitions and business combinations	238,396	311,406
Other intangible assets	5,852	4,888
	244,248	316,294
Less: accumulated amortization	71,404	76,458
Net intangible assets	172,844	239,836
Goodwill	63,107	63,094
Deferred tax assets, net	44,058	
Long-term investments	65,695	
Deferred financing costs, net	2,716	4,325
	\$ 1,008,513	\$ 1,145,955

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**MEDICIS PHARMACEUTICAL CORPORATION**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(in thousands, except share amounts)

	September 30, 2006 (unaudited)	December 31, 2005
<b>Liabilities</b>		
Current liabilities:		
Accounts payable	\$ 27,608	\$ 57,708
Short-term contract obligation		27,407
Income taxes payable	8,882	31,521
Other current liabilities	41,735	24,195
Total current liabilities	78,225	140,831
Long-term liabilities:		
Contingent convertible senior notes	453,065	453,065
Deferred tax liability, net		8,572
<b>Stockholders Equity</b>		
Preferred stock, \$0.01 par value; shares authorized: 5,000,000; no shares issued		
Class A common stock, \$0.014 par value; shares authorized: 150,000,000; issued and outstanding: 67,563,235 and 67,052,326 at September 30, 2006 and December 31, 2005, respectively		
	945	938
Class B common stock, \$0.014 par value; shares authorized: 1,000,000; no shares issued and outstanding at September 30, 2006 and December 31, 2005		
Additional paid-in capital	581,947	550,006
Accumulated other comprehensive income	877	379
Accumulated earnings	236,250	334,894
Less: Treasury stock, 12,654,233 and 12,647,554 shares at cost at September 30, 2006 and December 31, 2005, respectively	(342,796)	(342,730)
Total stockholders equity	477,223	543,487
	\$ 1,008,513	\$ 1,145,955

See accompanying notes to condensed consolidated financial statements.

Table of Contents

**MEDICIS PHARMACEUTICAL CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
**(unaudited)**  
**(in thousands, except per share data)**

	Three Months Ended		Nine Months Ended	
	September 30,		September 30,	
	2006	2005	2006	2005
Net product revenues	\$ 86,189	\$ 79,398	\$ 237,922	\$ 237,513
Net contract revenues	3,798	3,866	12,254	41,483
Net revenues	89,987	83,264	250,176	278,996
Cost of product revenue (1)	8,518	12,024	30,116	40,201
Gross profit	81,469	71,240	220,060	238,795
Operating expenses:				
Selling, general and administrative (2)	53,641	41,487	155,929	110,905
Impairment of long-lived assets	52,586		52,586	
Research and development (3)	8,983	5,053	149,968	25,590
Depreciation and amortization	5,854	6,308	17,510	18,435
Operating (loss) income	(39,595)	18,392	(155,933)	83,865
Interest and investment income	7,928	4,116	22,211	10,510
Interest expense	(2,666)	(2,666)	(7,982)	(7,982)
(Loss) income before income tax	(34,333)	19,842	(141,704)	86,393
Income tax (benefit) expense	(13,656)	7,382	(48,003)	30,167
Net (loss) income	\$ (20,677)	\$ 12,460	\$ (93,701)	\$ 56,226
Basic net (loss) income per share	\$ (0.38)	\$ 0.23	\$ (1.72)	\$ 1.04
Diluted net (loss) income per share	\$ (0.38)	\$ 0.20	\$ (1.72)	\$ 0.88
Cash dividend declared per common share	\$ 0.03	\$ 0.03	\$ 0.09	\$ 0.09
Basic common shares outstanding	54,747	54,310	54,536	54,275

Diluted common shares outstanding	54,747	69,850	54,536	69,513
(1) amounts exclude amortization of intangible assets related to acquired products	\$ 5,076	\$ 5,560	\$ 15,226	\$ 16,246
(2) amounts include share-based compensation expense	\$ 6,177	\$ 7,184	\$ 19,660	\$ 7,441
(3) amounts include share-based compensation expense	\$ 456	\$ 505	\$ 1,494	\$ 505

See accompanying notes to condensed consolidated financial statements.

**Table of Contents**

**MEDICIS PHARMACEUTICAL CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(unaudited)**  
**(in thousands)**

	Nine Months Ended	
	September 30, 2006	September 30, 2005
<b>Operating Activities:</b>		
Net (loss) income	\$ (93,701)	\$ 56,226
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:		
Depreciation and amortization	17,510	18,436
Amortization of deferred financing fees	1,608	1,608
Impairment of long-lived assets	52,586	
Loss on disposal of property and equipment	9	44
(Gain) loss on sale of available-for-sale investments	(358)	1,377
Share-based compensation expense	21,154	7,947
Deferred income tax (benefit) expense	(56,590)	13,598
Tax benefit from exercise of stock options	1,631	76
Excess tax benefits from share-based payment arrangements	(952)	(73)
Provision for doubtful accounts and returns	4,571	(3,866)
(Amortization) accretion of (discount)/premium on investments	(1,679)	1,536
Changes in operating assets and liabilities:		
Accounts receivable	21,154	6,256
Inventories	(1,008)	(2,781)
Other current assets	(5,391)	7,160
Accounts payable	(30,100)	5,184
Income taxes payable	(22,639)	797
Other current liabilities	17,456	(945)
Net cash (used in) provided by operating activities	(74,739)	112,580
<b>Investing Activities:</b>		
Purchase of property and equipment	(3,171)	(1,492)
Payment of direct merger costs	(27,420)	(8,472)
Payments for purchase of product rights	(964)	(490)
Purchase of available-for-sale investments	(664,473)	(432,412)
Sale of available-for-sale investments	211,624	451,553
Maturity of available-for-sale investments	214,583	101,340
Net cash (used in) provided by investing activities	(269,821)	110,027
<b>Financing Activities:</b>		
Payment of dividends	(4,926)	(4,884)
Excess tax benefits from share-based payment arrangements	952	73
Proceeds from the exercise of stock options	9,164	990
Net cash provided by (used in) financing activities	5,190	(3,821)



Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

Effect of exchange rate on cash and cash equivalents	150	31
Net (decrease) increase in cash and cash equivalents	(339,220)	218,817
Cash and cash equivalents at beginning of period	446,997	31,521
Cash and cash equivalents at end of period	\$ 107,777	\$ 250,338

See accompanying notes to condensed consolidated financial statements.

6

---

**Table of Contents**

**MEDICIS PHARMACEUTICAL CORPORATION**  
**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**September 30, 2006**  
**(unaudited)**

**1. NATURE OF BUSINESS**

Medicis Pharmaceutical Corporation ( Medicis or the Company ) is a leading specialty pharmaceutical company focusing primarily on the development and marketing of products in the United States ( U.S. ) for the treatment of dermatological, aesthetic and podiatric conditions. Medicis also markets products in Canada for the treatment of dermatological and aesthetic conditions.

The Company offers a broad range of products addressing various conditions including acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin). Medicis currently offers 16 branded products. As of September 30, 2006, its core brands are OMNICEF® (cefdinir), RESTYLANE® (hyaluronic acid), SOLODYN (minocycline HCl, USP) Extended Release Tablets, TRIAZ® (benzoyl peroxide), and VANOS (fluocinonide) Cream, 0.1%.

In March 2003, Medicis expanded into the dermal aesthetic market through its acquisition of the exclusive U.S. and Canadian rights to market, distribute and commercialize the dermal restorative product lines known as RESTYLANE®, PERLANE® and RESTYLANE FINE LINES from Q-Med AB, a Swedish biotechnology/medical device company and its affiliates, collectively Q-Med. RESTYLANE® has been approved by the Food and Drug Administration (the FDA ) for use in the U.S. as a medical device for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. RESTYLANE®, PERLANE® and RESTYLANE FINE LINES have been approved for use in Canada.

On March 17, 2006, Medicis entered into a development and distribution agreement with Ipsen Ltd., a wholly-owned subsidiary of Ipsen S.A. ( Ipsen ), whereby Ipsen granted Aesthetica Ltd., a wholly-owned subsidiary of Medicis, rights to develop, distribute and commercialize Ipsen s botulinum toxin product in the U.S., Canada and Japan for aesthetic use by physicians. The product is commonly referred to as RELOXIN® in the U.S. aesthetic market and DYSPORT® for medical and aesthetic markets outside the U.S. The product is not currently approved for use in the U.S., Canada or Japan.

The consolidated financial statements include the accounts of Medicis Pharmaceutical Corporation and its wholly owned subsidiaries. The Company does not have any subsidiaries in which it does not own 100% of the outstanding stock. All of the Company s subsidiaries are included in the consolidated financial statements. All significant intercompany accounts and transactions have been eliminated in consolidation.

The accompanying interim condensed consolidated financial statements of Medicis have been prepared in conformity with U.S. generally accepted accounting principles, consistent in all material respects with those applied in the Company s Transition Report on Form 10-K/T for the six-month period ended December 31, 2005 (the Transition Period ). The financial information is unaudited, but reflects all adjustments, consisting only of normal recurring accruals, which are, in the opinion of the Company s management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The information included in this Form 10-Q should be read in conjunction with the Company s Transition Report on Form 10-K/T for the Transition Period. Certain prior period amounts have been reclassified to conform with current period presentation.

**Table of Contents****2. SHARE-BASED COMPENSATION**

At September 30, 2006, the Company had seven active share-based employee compensation plans. Of these seven share-based compensation plans, only the 2006 Incentive Award Plan is eligible for the granting of future awards. Stock option awards granted from these plans are granted at the fair market value on the date of grant. The option awards vest over a period determined at the time the options are granted, ranging from one to five years, and generally have a maximum term of ten years. Certain options provide for accelerated vesting if there is a change in control (as defined in the plans). When options are exercised, new shares of the Company's Class A common stock are issued. Effective July 1, 2005, the Company adopted SFAS No. 123R using the modified prospective method. Other than restricted stock, no share-based employee compensation cost has been reflected in net income prior to the adoption of SFAS No. 123R. Results for prior periods have not been restated.

The adoption of SFAS No. 123R increased the net loss before income tax benefit for the three and nine months ended September 30, 2006 by approximately \$6.6 million and \$21.2 million, respectively, and increased the net loss for the three and nine months ended September 30, 2006 by approximately \$4.8 million and \$15.3 million, respectively. As a result, the net loss per common share for the three and nine months ended September 30, 2006 was increased \$0.09 and \$0.28, respectively.

The total value of the stock option awards is expensed ratably over the service period of the employees receiving the awards. As of September 30, 2006, total unrecognized compensation cost related to stock option awards, to be recognized as expense subsequent to September 30, 2006, was approximately \$45.4 million and the related weighted-average period over which it is expected to be recognized is approximately 2.4 years.

Prior to the adoption of SFAS No. 123R, the Company presented all tax benefits of deductions resulting from the exercise of stock options as operating cash flows in the condensed consolidated statements of cash flows. SFAS No. 123R requires the cash flows resulting from the tax benefits resulting from tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) to be classified as financing cash flows. Approximately \$0.4 million and \$1.0 million of excess tax benefits were recognized during the three months and nine months ended September 30, 2006, respectively.

A summary of stock options activity within the Company's stock-based compensation plans and changes for the nine months ended September 30, 2006 is as follows:

	<b>Number of Shares</b>	<b>Weighted Average Exercise Price</b>	<b>Weighted Average Remaining Contractual Term</b>	<b>Aggregate Intrinsic Value</b>
Balance at December 31, 2005	14,379,336	\$27.21		
Granted	91,125	\$31.38		
Exercised	(521,593)	\$19.25		
Terminated/expired	(313,604)	\$30.55		
Balance at September 30, 2006	13,635,264	\$27.46	5.79	\$82,585,498

The intrinsic value of options exercised during the nine months ended September 30, 2006 was \$6,042,317. Options exercisable under the Company's share-based compensation plans at September 30, 2006 were 9,015,175 with an average exercise price of \$25.26, an average remaining contractual term of 5.1 years, and an aggregate intrinsic value of \$68,814,253.

**Table of Contents**

A summary of fully vested stock options and stock options expected to vest, based on historical forfeiture rates, as of September 30, 2006, is as follows:

	<b>Number of Shares</b>	<b>Weighted Average Exercise Price</b>	<b>Weighted Average Remaining Contractual Term</b>	<b>Aggregate Intrinsic Value</b>
Outstanding	13,135,122	\$27.44	5.8	\$79,786,443
Exercisable	8,724,167	\$25.25	5.1	\$66,675,811

The fair value of each stock option award is estimated on the date of the grant using the Black-Scholes option pricing model. The fair value of stock option awards granted during the nine months ended September 30, 2006 and September 30, 2005 were estimated with the following assumptions:

	<b>Nine Months Ended September 30, 2006</b>	<b>Nine Months Ended September 30, 2005</b>
Expected dividend yield	0.4%	0.3% to 0.4%
Expected stock price volatility	0.36	0.36 to 0.44
Risk-free interest rate	4.5% to 4.6%	3.6% to 4.2%
Expected life of options	7 Years	5 to 8 Years

The expected dividend yield is based on expected annual dividends to be paid by the Company as a percentage of the market value of the Company's stock as of the date of grant. The Company determined that a blend of implied volatility and historical volatility is more reflective of market conditions and a better indicator of expected volatility than using purely historical volatility. The risk-free interest rate is based on the U.S. treasury security rate in effect as of the date of grant. The expected lives of options are based on historical data of the Company.

The weighted average fair value of stock options granted during the nine months ended September 30, 2006 and 2005 was \$14.00 and \$14.15, respectively.

The following table illustrates the effect on net income and net income per common share as if the Company had applied the fair value recognition provisions of SFAS No. 123 to all outstanding stock option awards for periods presented that include periods prior to the Company's July 1, 2005, adoption of SFAS No. 123R (amounts in thousands, except per share amounts):

	<b>NINE MONTHS ENDED SEPTEMBER 30, 2005</b>
Net income, as reported	\$ 56,226
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects	11,618
Pro-forma net income	\$ 44,608
Net income per common share:	
Basic, as reported	\$ 1.04
Basic, pro forma	\$ 0.82

Diluted, as reported		\$	0.88
Diluted, pro forma		\$	0.71

---

**Table of Contents**

The Company also grants restricted stock awards to certain employees. Restricted stock awards are valued at the closing market value of the Company's Class A common stock on the date of grant, and the total value of the award is expensed ratably over the service period of the employees receiving the grants. During the nine months ended September 30, 2006, 158,025 shares of restricted stock were granted to certain employees. Share-based compensation expense related to all restricted stock awards outstanding during the three months and nine months ended September 30, 2006, was approximately \$0.5 million and \$1.5 million, respectively. Share-based compensation expense related to all restricted stock awards outstanding during the three months and nine months ended September 30, 2005, was approximately \$0.3 million and \$0.6 million, respectively. As of September 30, 2006, the total amount of unrecognized compensation cost related to nonvested restricted stock awards, to be recognized as expense subsequent to September 30, 2006, was approximately \$7.7 million, and the related weighted-average period over which it is expected to be recognized is approximately 4.1 years.

A summary of restricted stock activity within the Company's share-based compensation plans and changes for the nine months ended September 30, 2006 is as follows (amounts in thousands, except per share amounts):

<b>Nonvested Shares</b>	<b>Shares</b>	<b>Weighted-Average Grant-Date Fair Value</b>
Nonvested at December 31, 2005	212,260	\$29.65
Granted	158,025	\$28.68
Vested	(69,456)	\$26.07
Forfeited	(2,000)	\$32.06
Nonvested at September 30, 2006	298,829	\$29.95

The total fair value of restricted shares vested during the nine months ended September 30, 2006 and 2005 was approximately \$1.8 million and \$0.6 million, respectively.

### **3. RESEARCH AND DEVELOPMENT COSTS AND ACCOUNTING FOR STRATEGIC COLLABORATIONS**

All research and development costs, including payments related to products under development and research consulting agreements, are expensed as incurred. The Company may continue to make non-refundable payments to third parties for new technologies and for research and development work that has been completed. These payments may be expensed at the time of payment depending on the nature of the payment made.

The Company's policy on accounting for costs of strategic collaborations determines the timing of the recognition of certain development costs. In addition, this policy determines whether the cost is classified as development expense or capitalized as an asset. Management is required to form judgments with respect to the commercial status of such products in determining whether development costs meet the criteria for immediate expense or capitalization. For example, when the Company acquires certain products for which there is already an Abbreviated New Drug Application (ANDA) or a New Drug Application (NDA) approval related directly to the product, and there is net realizable value based on projected sales for these products, the Company capitalizes the amount paid as an intangible asset. In contrast, if the Company acquires product rights which are in the development phase and to which the Company has no assurance that the third party will successfully complete its developmental milestones or that the product will gain regulatory approval, the Company expenses such payments.

On January 28, 2005, the Company amended its strategic alliance with AAIPharma Inc. (AAIPharma) previously initiated in June 2002 for the development, commercialization and license of a dermatologic product. The amendment allowed for the immediate transfer of the work product, as defined under the agreement, as well as the work product's management and development, to Medicis, and provided that AAIPharma would continue to assist Medicis with the

development of the product on a fee

**Table of Contents**

for services basis. Medicis will have no future financial obligations to pay AAIPharma on the attainment of clinical milestones, but incurred approximately \$8.3 million as a charge to research and development expense during the three months ended March 31, 2005, as part of the amendment and the assumption of all liabilities associated with the project.

#### **4. DEVELOPMENT AND DISTRIBUTION AGREEMENT WITH IPSEN FOR RIGHTS TO IPSEN'S BOTULINUM TOXIN PRODUCT KNOWN AS RELOXIN®**

On March 17, 2006, the Company entered into a development and distribution agreement with Ipsen, whereby Ipsen granted Aesthetica Ltd., a wholly-owned subsidiary of Medicis, rights to develop, distribute and commercialize Ipsen's botulinum toxin product in the United States, Canada and Japan for aesthetic use by physicians. The product is commonly referred to as RELOXIN® in the U.S. aesthetic market and DYSPORT® in medical and aesthetic markets outside the U.S. The product is not currently approved for use in the U.S., Canada or Japan. Upon execution of the development and distribution agreement, Medicis made an initial payment to Ipsen in the amount of \$90.1 million in consideration for the exclusive distribution rights in the U.S., Canada and Japan.

Additionally, Medicis and Ipsen agreed to negotiate and enter into an agreement relating to the exclusive distribution and development rights of the product for the aesthetic market in Europe, and subsequently in certain other markets. Under the terms of the U.S., Canada and Japan agreement, Medicis was obligated to make an additional \$35.1 million payment, as amended, to Ipsen if this agreement was not entered into by April 15, 2006. On April 13, 2006, Medicis and Ipsen agreed to extend this deadline to July 15, 2006. In connection with this extension, Medicis paid Ipsen approximately \$12.9 million in April 2006, which would be applied against the total obligation, in the event an agreement was not entered into by the extended deadline. On July 17, 2006, Medicis and Ipsen agreed that the two companies would not pursue an agreement for the commercialization of the product outside of the U.S., Canada and Japan. On July 17, 2006, Medicis made the additional \$22.2 million payment to Ipsen, representing the remaining portion of the \$35.1 million total obligation, resulting from the discontinuance of negotiations for other territories.

The initial \$90.1 million payment was recognized as a charge to research and development expense during the three months ended March 31, 2006, and the \$35.1 million obligation was recognized as a charge to research and development expense during the three months ended June 30, 2006.

Medicis will pay an additional \$26.5 million upon successful completion of various clinical and regulatory milestones, \$75.0 million upon the product's approval by the FDA and \$2.0 million upon regulatory approval of the product in Japan. Ipsen will manufacture and provide the product to Medicis for the term of the agreement, which extends to September 2019. Ipsen will receive a royalty based on sales and a supply price, the total of which is equivalent to approximately 30% of net sales as defined under the agreement. Under the terms of the agreement, Medicis is responsible for all remaining research and development costs associated with obtaining the product's approval in the U.S., Canada and Japan.

#### **5. MERGER OF ASCENT PEDIATRICS, INC.**

As part of its merger with Ascent completed in November 2001, the Company may be required to make contingent purchase price payments (Contingent Payments) for each of the first five years following closing based upon reaching certain sales threshold milestones on the Ascent products for each twelve month period through November 15, 2006, subject to certain deductions and set-offs. From time to time the Company assesses the probability and likelihood of payment in the coming respective November period based on current sales trends. A total of approximately \$27.4 million was included in short-term contract obligation in the Company's condensed consolidated balance sheets as of December 31, 2005, representing the first four years' Contingent Payments. Pursuant to the merger agreement, payment of the contingent portion of the purchase price was withheld pending the final outcome of certain pending litigation. The Company distributed the accumulated \$27.4 million in Contingent Payments to the former shareholders of Ascent during the three months ended March 31, 2006, as the pending litigation matter was settled in Medicis favor. In addition, the Company settled an additional dispute during May 2006, which was initiated in March 2006, relating to the concluded lawsuit. A \$1.8 million settlement was recognized as a charge to selling, general and administrative expense during the three months ended March 31, 2006.





**Table of Contents****6. IMPAIRMENT OF LONG-LIVED ASSETS**

The Company assesses the potential impairment of long-lived assets on a periodic basis and when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant under-performance of a product line in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the Company's use of the assets. Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying amount of the asset grouping to the Company's estimate of the related total future net cash flows. If an asset carrying value is not recoverable through the related cash flows, the asset is considered to be impaired. The impairment is measured by the difference between the asset grouping's carrying amount and its fair value, based on the best information available, including market prices or discounted cash flow analysis.

During the quarter ended September 30, 2006, long-lived assets related to certain of the Company's products were determined to be impaired based on the Company's analysis of the long-lived assets' carrying value and projected future cash flows. As a result of the impairment analysis, the Company recorded a write-down of approximately \$52.6 million related to these long-lived assets. This write-down included the following (in thousands):

Long-lived asset related to LOPROX® products	\$ 49,163
Long-lived asset related to ESOTERICA® products	3,267
Other long-lived asset	156
	<b>\$ 52,586</b>

Factors affecting the future cash flows of the LOPROX® long-lived asset included competitive pressures in the marketplace and the cancellation of the development plan to support future forms of LOPROX®. Factors affecting the future cash flows of the ESOTERICA® long-lived asset included a notice of proposed rulemaking by the FDA for an NDA to be required for continued marketing of hydroquinone products, such as ESOTERICA®. ESOTERICA® is currently an over-the-counter product line, and the Company does not plan to invest in obtaining an approved NDA for this product line if this proposed rule is made final without change.

In addition, as a result of the impairment analysis, the remaining amortizable lives of the long-lived assets related to LOPROX® and ESOTERICA® were reduced to fifteen years and fifteen months, respectively. The long-lived asset related to LOPROX® will become fully amortized on September 30, 2021, and the long-lived asset related to ESOTERICA® will become fully amortized on December 31, 2007. The net impact on amortization expense as a result of the write-down of the carrying value of the long-lived assets and the reduction of their respective amortizable lives is a decrease in quarterly amortization expense related to LOPROX® of \$354,051 and an increase in quarterly amortization expense related to ESOTERICA® of \$48,077.

**7. SHORT-TERM AND LONG-TERM INVESTMENTS**

The Company's short-term and long-term investments are intended to establish a high-quality portfolio that preserves principal, meets liquidity needs, avoids inappropriate concentrations and delivers an appropriate yield in relationship to the Company's investment guidelines and market conditions. Short-term and long-term investments consist of corporate and various government agency and municipal debt securities. Management classifies the Company's short-term and long-term investments as available-for-sale. Available-for-sale securities are carried at fair value with unrealized gains and losses reported in stockholders' equity. Realized gains and losses and declines in value judged to be other than temporary, if any, are included in operations. A decline in the market value of any available-for-sale security below cost that is deemed to be other than temporary, results in an impairment in the fair value of the investment. The impairment is charged to earnings and a new cost basis for the security is established. Premiums and discounts are amortized or accreted over the life of the related available-for-sale security. Dividends and interest income are recognized when earned. The cost of securities sold is calculated using the specific identification method. At September 30, 2006, the Company has recorded the estimated fair value in



**Table of Contents**

available-for-sale securities for short-term and long-term investments of approximately \$470.5 million and \$65.7 million, respectively.

The following is a summary of available-for-sale securities (amounts in thousands):

	Cost	SEPTEMBER 30, 2006		Gross Fair Value
		Gross Unrealized Gains	Gross Unrealized Losses	
U.S. corporate securities	\$ 260,943	\$ 117	\$ 236	\$ 260,824
Other debt securities	275,298	106	41	275,363
Total securities	\$ 536,241	\$ 223	\$ 277	\$ 536,187

During the three months and nine months ended September 30, 2006, the gross realized gains on sales of available-for-sale securities totaled \$131,355 and \$361,934 respectively, while gross realized losses on sales of available-for-sale securities were immaterial for the three months and nine months ended September 30, 2006. Such amounts of gains and losses are determined based on the specific identification method and are included in interest and investment income. The net adjustment to unrealized gains during the three months and nine months ended September 30, 2006, on available-for-sale securities included in stockholders' equity totaled \$392,340 and \$348,450, respectively. The amortized cost and estimated fair value of the available-for-sale securities at September 30, 2006, by maturity, are shown below (amounts in thousands):

	SEPTEMBER 30, 2006	
	Cost	Estimated Fair Value
<b>Available-for-sale</b>		
Due in one year or less	\$ 231,534	\$ 231,471
Due after one year through five years	188,023	188,023
Due after five years through 10 years		
Due after 10 years	116,684	116,693
	\$ 536,241	\$ 536,187

At September 30, 2006, approximately \$239.0 million of the \$304.7 million in estimated fair value expected to mature greater than one year has been classified as short-term investments since these investments are in an unrealized gain position. Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties, and the Company views its available-for-sale securities as available for current operations.

The following table shows the gross unrealized losses and fair value of the Company's investments with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position at September 30, 2006 (amounts in thousands):

	Less Than 12 Months		Greater Than 12 Months	
	Fair Value	Gross Unrealized Loss	Fair Value	Gross Unrealized Loss
U.S. corporate securities	\$ 179,338	\$ 176	\$ 12,869	\$ 60
Other debt securities	48,776	26	2,835	15

Total securities	\$ 228,114	\$ 202	\$ 15,704	\$ 75
------------------	------------	--------	-----------	-------

The unrealized losses on the Company's investments were caused primarily by interest rate increases. It is expected that the investments will not be settled at a price less than the amortized cost. Because the Company has the ability to and intent to hold these investments until a recovery of fair value,

13

---

**Table of Contents**

which may be maturity, the Company does not consider these investments to be other than temporarily impaired at September 30, 2006.

**8. SEGMENT AND PRODUCT INFORMATION**

The Company operates in one significant business segment: Pharmaceuticals. The Company's current pharmaceutical franchises are divided between the dermatological and non-dermatological fields. The dermatological field represents products for the treatment of acne and acne-related dermatological conditions and non-acne dermatological conditions. The non-dermatological field represents products for the treatment of urea cycle disorder and contract revenue. The acne and acne-related dermatological product lines include DYNACIN<sup>®</sup>, PLEXION<sup>®</sup>, SOLODYN<sup>™</sup> and TRIAZ<sup>®</sup>. The non-acne dermatological product lines include LOPROX<sup>®</sup>, OMNICEF<sup>®</sup>, RESTYLANE<sup>®</sup> and VANOS<sup>™</sup>. The non-dermatological product lines include AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup>. The non-dermatological field also includes contract revenues associated with licensing agreements and authorized generics.

The Company's pharmaceutical products, with the exception of AMMONUL<sup>®</sup> and BUPHENYL<sup>®</sup>, are promoted to dermatologists, podiatrists and plastic surgeons. Such products are often prescribed by physicians outside these three specialties; including family practitioners, general practitioners, primary-care physicians and OB/GYNs, as well as hospitals, government agencies and others. All products, with the exception of BUPHENYL<sup>®</sup>, are sold primarily to wholesalers and retail chain drug stores. BUPHENYL<sup>®</sup> is primarily sold directly to hospitals and pharmacies.

The percentage of net revenues for each of the product categories is as follows:

	<b>THREE MONTHS ENDED SEPTEMBER 30, 2006</b>		<b>NINE MONTHS ENDED SEPTEMBER 30, 2006</b>	
	<b>2006</b>	<b>2005</b>	<b>2006</b>	<b>2005</b>
Acne and acne-related dermatological products	47%	33%	37%	28%
Non-acne dermatological products	46	56	53	52
Non-dermatological products	7	11	10	20
Total net revenues	100%	100%	100%	100%

**9. INVENTORIES**

The Company utilizes third parties to manufacture and package inventories held for sale, takes title to certain inventories once manufactured, and warehouses such goods until packaged for final distribution and sale. Inventories consist of salable products held at the Company's warehouses, as well as raw materials and components at the manufacturers' facilities, and are valued at the lower of cost or market using the first-in, first-out method. The Company provides valuation reserves for estimated obsolescence or unmarketable inventory in an amount equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions.

Inventories are as follows (amounts in thousands):

	September 30, 2006	December 31, 2005
Raw materials	\$ 7,551	\$ 6,436
Finished goods	13,487	13,925
Valuation reserve	(954)	(1,285)
Total inventories	\$ 20,084	\$ 19,076

**10. CONTINGENT CONVERTIBLE SENIOR NOTES**

In June 2002, the Company sold \$400.0 million aggregate principal amount of its 2.5% Contingent Convertible Notes Due 2032 (the Old Notes ) in private transactions. As discussed below, approximately \$230.8 million in principal amount of the Old Notes was exchanged for New Notes on August 14, 2003. The Old Notes bear interest at a rate of 2.5% per annum, which is payable on June 4 and December 4 of each year, beginning on December 4, 2002. The Company also agreed to pay contingent

**Table of Contents**

interest at a rate equal to 0.5% per annum during any six-month period, with the initial six-month period commencing June 4, 2007, if the average trading price of the Old Notes reaches certain thresholds. The Old Notes will mature on June 4, 2032.

The Company may redeem some or all of the Old Notes at any time on or after June 11, 2007, at a redemption price, payable in cash, of 100% of the principal amount of the Old Notes, plus accrued and unpaid interest, including contingent interest, if any. Holders of the Old Notes may require the Company to repurchase all or a portion of their Old Notes on June 4, 2007, 2012 and 2017; and upon a change in control, as defined in the indenture governing the Old Notes, at 100% of the principal amount of the Old Notes, plus accrued and unpaid interest to the date of the repurchase, payable in cash.

The Old Notes are convertible, at the holders' option, prior to the maturity date into shares of the Company's Class A common stock in the following circumstances:

during any quarter commencing after June 30, 2002, if the closing price of the Company's Class A common stock over a specified number of trading days during the previous quarter, including the last trading day of such quarter, is more than 110% of the conversion price of the Old Notes, or \$31.96. The Old Notes are initially convertible at a conversion price of \$29.05 per share, which is equal to a conversion rate of approximately 34.4234 shares per \$1,000 principal amount of Old Notes, subject to adjustment;

if the Company has called the Old Notes for redemption;

during the five trading day period immediately following any nine consecutive day trading period in which the trading price of the Old Notes per \$1,000 principal amount for each day of such period was less than 95% of the product of the closing sale price of the Company's Class A common stock on that day multiplied by the number of shares of the Company's Class A common stock issuable upon conversion of \$1,000 principal amount of the Old Notes; or

upon the occurrence of specified corporate transactions.

The Old Notes, which are unsecured, do not contain any restrictions on the payment of dividends, the incurrence of additional indebtedness or the repurchase of the Company's securities and do not contain any financial covenants.

The Company incurred \$12.6 million of fees and other origination costs related to the issuance of the Old Notes. The Company is amortizing these costs over the five-year Put period, which runs through May 2007. The Put period runs from the date the Old Notes were issued to the date the Company may redeem some or all of the Old Notes.

On August 14, 2003, the Company exchanged approximately \$230.8 million in principal amount of its Old Notes for approximately \$283.9 million in principal amount of its 1.5% Contingent Convertible Senior Notes Due 2033 (the New Notes). Holders of Old Notes that accepted the Company's exchange offer received \$1,230 in principal amount of New Notes for each \$1,000 in principal amount of Old Notes. The terms of the New Notes are similar to the terms of the Old Notes, but have a different interest rate, conversion rate and maturity date. Holders of Old Notes that chose not to exchange continue to be subject to the terms of the Old Notes.

The New Notes bear interest at a rate of 1.5% per annum, which is payable on June 4 and December 4 of each year, beginning December 4, 2003. The Company will also pay contingent interest at a rate of 0.5% per annum during any six-month period, with the initial six-month period commencing June 4, 2008, if the average trading price of the New Notes reaches certain thresholds. The New Notes mature on June 4, 2033.

The Company may redeem some or all of the New Notes at any time on or after June 11, 2008, at a redemption price, payable in cash, of 100% of the principal amount of the New Notes, plus accrued and unpaid interest, including contingent interest, if any. Holders of the New Notes may require the Company to repurchase all or a portion of their New Notes on June 4, 2008, 2013 and 2018, and upon a change in



**Table of Contents**

control, as defined in the indenture governing the New Notes, at 100% of the principal amount of the New Notes, plus accrued and unpaid interest to the date of the repurchase, payable in cash.

The New Notes are convertible, at the holders' option, prior to the maturity date into shares of the Company's Class A common stock in the following circumstances:

during any quarter commencing after September 30, 2003, if the closing price of the Company's Class A common stock over a specified number of trading days during the previous quarter, including the last trading day of such quarter, is more than 120% of the conversion price of the New Notes, or \$46.51. The Notes are initially convertible at a conversion price of \$38.76 per share, which is equal to a conversion rate of approximately 25.7998 shares per \$1,000 principal amount of New Notes, subject to adjustment;

if the Company has called the New Notes for redemption;

during the five trading day period immediately following any nine consecutive day trading period in which the trading price of the New Notes per \$1,000 principal amount for each day of such period was less than 95% of the product of the closing sale price of the Company's Class A common stock on that day multiplied by the number of shares of the Company's Class A common stock issuable upon conversion of \$1,000 principal amount of the New Notes; or

upon the occurrence of specified corporate transactions.

The New Notes, which are unsecured, do not contain any restrictions on the incurrence of additional indebtedness or the repurchase of the Company's securities and do not contain any financial covenants. The New Notes require an adjustment to the conversion price if the cumulative aggregate of all current and prior dividend increases above \$0.025 per share would result in at least a one percent (1%) increase in the conversion price. This threshold has not been reached and no adjustment to the conversion price has been made.

As a result of the exchange, the outstanding principal amounts of the Old Notes and the New Notes were \$169.2 million and \$283.9 million, respectively. Both the New Notes and Old Notes are reported in aggregate on the Company's condensed consolidated balance sheets. The Company incurred approximately \$5.1 million of fees and other origination costs related to the issuance of the New Notes. The Company is amortizing these costs over the five-year Put period, which runs through August 2008. The Put period runs from the date the New Notes were issued to the date the Company may redeem some or all of the New Notes.

During the quarters ended December 31, 2005, September 30, 2005, December 31, 2004, September 30, 2004, June 30, 2004, March 31, 2004 and December 31, 2003, the Old Notes met the criteria for the right of conversion into shares of the Company's Class A common stock. This right of conversion of the holders of Old Notes was triggered by the stock closing above \$31.96 on 20 of the last 30 trading days and the last trading day of the quarters ended December 31, 2005, September 30, 2005, December 31, 2004, September 30, 2004, June 30, 2004, March 31, 2004 and December 31, 2003. The holders of Old Notes had this conversion right only until March 31, 2006. During the quarters ended September 30, 2006, June 30, 2006, March 31, 2006, June 30, 2005 and March 31, 2005, the Old Notes did not meet the criteria for the right of conversion. At the end of all future quarters, the conversion rights will be reassessed in accordance with the bond indenture agreement to determine if the conversion trigger rights have been achieved. During the three months ended September 30, 2004 and March 31, 2004, outstanding principal amounts of \$2,000 and \$6,000 of Old Notes, respectively, were converted into shares of the Company's Class A common stock. As of November 8, 2006, no other Old Notes had been converted.

**11. INCOME TAXES**

Income taxes are determined using an annual effective tax rate, which generally differs from the U.S. Federal statutory rate, primarily because of state and local income taxes, charitable contribution deductions, tax credits available in the U.S., the treatment of certain share-based payments under SFAS

**Table of Contents**

123R that are not designed to normally result in tax deductions, and differences in tax rates in certain non-U.S. jurisdictions. The Company's effective tax rate may be subject to fluctuations during the year as new information is obtained which may affect the assumptions the Company uses to estimate its annual effective tax rate, including factors such as the Company's mix of pre-tax earnings in the various tax jurisdictions in which the Company operates, changes in valuation allowances against deferred tax assets, reserves for tax audit issues and settlements, utilization of tax credits and changes in tax laws in jurisdictions where the Company conducts operations. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities, along with net operating losses and credit carryforwards. The Company records valuation allowances against deferred tax assets to reduce the net carrying values to amounts that are more likely than not to be realized.

The benefit for income taxes for the nine months ended September 30, 2006, includes a \$5.1 million tax benefit relating to the resolution of certain income tax examinations for tax years ended through June 30, 2004.

At September 30, 2006, the Company has a federal net operating loss carryforward of approximately \$61.7 million that begins expiring in varying amounts in the years 2008 through 2020 if not previously utilized. The net operating loss carryforward was acquired in connection with the Company's merger with Ascent during fiscal 2002. As a result of the merger and related ownership change for Ascent, the annual utilization of the net operating loss carryforward is limited under Internal Revenue Code Section 382. Based upon this limitation, the Company estimates that approximately \$15.2 million of the \$61.7 million net operating loss carryforward will be realized. Accordingly, a valuation reserve has been recorded for the remaining net operating loss carryforward that is not expected to be realized.

At September 30, 2006, the Company had a research and development credit carryforward of approximately \$1.3 million that begins expiring in varying amounts in the years 2008 through 2020 if not previously utilized. All of the research and development credit carryforward was acquired in connection with the Company's merger with Ascent during fiscal 2002 and is subject to the limitation under Internal Revenue Code Section 383. As a result of this limitation, the Company does not expect to realize any of the research and development credits acquired from Ascent. Accordingly, a valuation reserve of \$1.3 million has been established for the acquired research and development credits.

As a result of the limitations described above, the Company recorded a deferred tax asset valuation allowance of \$17.5 million related to the net operating loss and research and development credit carryforwards acquired in the merger with Ascent. Subsequent realization of loss and credit carryforwards in excess of the amounts estimated to be realized as of September 30, 2006 will be applied to reduce the valuation allowance and goodwill recorded in connection with the merger with Ascent.

The Company took advantage of additional tax deductions available relating to the exercise of non-qualified stock options, disqualified dispositions of incentive stock options and vesting of restricted shares. Accordingly, the Company recorded a reduction to taxes payable and deferred tax assets of \$2.4 million and \$0.8 million, respectively, and recorded an increase to equity of \$1.6 million for the nine months ended September 30, 2006. Quarterly adjustments for the exercise of non-qualified stock options, disqualified dispositions of incentive stock options, and vesting of restricted shares may vary as they relate to the actions of the option holder or shareholder.

During the nine months ended September 30, 2006 and September 30, 2005, the Company made net tax payments of \$29.8 million and \$16.0 million, respectively.

**12. DIVIDENDS DECLARED ON COMMON STOCK**

On September 14, 2006, the Company declared a cash dividend of \$0.03 per issued and outstanding share of its Class A common stock payable on October 31, 2006 to stockholders of record at the close of business on October 2, 2006. The \$1.7 million dividend was recorded as a reduction of accumulated earnings and is included in other current liabilities in the accompanying condensed consolidated balance sheets as of September 30, 2006.

**Table of Contents****13. COMPREHENSIVE (LOSS) INCOME**

Total comprehensive (loss) income includes net (loss) income and other comprehensive income, which consists of foreign currency translation adjustments and unrealized gains and losses on available-for-sale investments. Total comprehensive loss for the three months and nine months ended September 30, 2006 was \$(20.3) million and \$(93.2) million, respectively. Total comprehensive income for the three months and nine months ended September 30, 2005 was \$13.2 million and \$56.8 million, respectively.

**14. NET (LOSS) INCOME PER COMMON SHARE**

The following table sets forth the computation of basic and diluted net (loss) income per common share (in thousands, except per share amounts):

	<b>THREE MONTHS ENDED SEPTEMBER 30, 2006</b>		<b>NINE MONTHS ENDED SEPTEMBER 30, 2006</b>	
	<b>2006</b>	<b>2005</b>	<b>2006</b>	<b>2005</b>
<b>BASIC</b>				
Net (loss) income	\$ (20,677)	\$ 12,460	\$ (93,701)	\$ 56,226
Weighted average number of common shares outstanding	54,747	54,310	54,536	54,275
Basic net (loss) income per common share	\$ (0.38)	\$ 0.23	\$ (1.72)	\$ 1.04
<b>DILUTED</b>				
Net (loss) income	\$ (20,677)	\$ 12,460	\$ (93,701)	\$ 56,226
Add:				
Tax-effected interest expense and issue costs related to Old Notes		841		2,513
Tax-effected interest expense and issue costs related to New Notes		839		2,516
Net (loss) income assuming dilution	\$ (20,677)	\$ 14,140	\$ (93,701)	\$ 61,255
Weighted average number of common shares	54,747	54,310	54,536	54,275
Effect of dilutive securities:				
Old Notes		5,823		5,823
New Notes		7,325		7,325
Stock options and restricted stock		2,392		2,090
Weighted average number of common shares assuming dilution	54,747	69,850	54,536	69,513

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 10-Q

Diluted net (loss) income per common share	\$ (0.38)	\$ 0.20	\$ (1.72)	\$ 0.88
--	-----------	---------	-----------	---------

Diluted net (loss) income per common share must be calculated using the if-converted method in accordance with EITF 04-8, Effect of Contingently Convertible Debt on Earnings per Share. Diluted net (loss) income per common share is calculated by adjusting net (loss) income for tax-effected net interest and issue costs on the Old Notes and New Notes, divided by the weighted average number of common shares outstanding assuming conversion.

18

---

**Table of Contents**

Due to the Company's net loss during the three months ended September 30, 2006, a calculation of diluted earnings per share is not required. For the three months ended September 30, 2006, potentially dilutive securities consisted of restricted stock and stock options convertible into 1,716,419 shares in the aggregate, and 5,822,894 and 7,324,819 shares of common stock, issuable upon conversion of the Old Notes and New Notes, respectively.

Due to the Company's net loss during the nine months ended September 30, 2006, a calculation of diluted earnings per share is not required. For the nine months ended September 30, 2006, potentially dilutive securities consisted of restricted stock and stock options convertible into 1,989,589 shares in the aggregate, and 5,822,894 and 7,324,819 shares of common stock, issuable upon conversion of the Old Notes and New Notes, respectively.

The diluted net income per common share computation for the three months ended September 30, 2005 excludes 5,501,851 shares of stock, respectively, that represented outstanding stock options whose exercise price were greater than the average market price of the common shares during the period and were anti-dilutive.

Diluted net income per common share for the nine months ended September 30, 2005 was calculated using the average of the periodic diluted common shares outstanding during the nine-month period. For the period from January 1, 2005 to June 30, 2005, diluted common shares outstanding was calculated using APB Opinion No. 25, while for the period from July 1, 2005 to September 30, 2005, diluted common shares outstanding was calculated using SFAS No. 123R. The Company adopted SFAS No. 123R effective July 1, 2005.

**15. CONTINGENCIES**

The government notified the Company on December 14, 2004, that it is investigating claims that the Company violated the federal False Claims Act in connection with the alleged off-label marketing and promotion of LOPROX® and LOPROX® TS products ( LOPROX® ) to pediatricians during periods prior to the Company's May 2004 disposition of the Company's pediatric sales division. In April 2006, the Company offered \$6.0 million to resolve the government's civil claims contingent on the execution of appropriate releases. The Justice Department countered with a demand of \$12.8 million to resolve the civil claims that the government is prepared to pursue. In May 2006, the Company countered with an offer of \$8.0 million that was contingent on resolving other aspects of the government's investigation to the satisfaction of the Company. In June 2006, the Justice Department countered with a \$10.0 million offer for settlement. On or around October 5, 2006 the parties agreed in principle to resolve all federal and state civil claims against the Company for \$9.8 million. Accordingly, the Company has accrued a loss contingency of \$9.8 million as of September 30, 2006, related to this matter, of which \$6.0 million was recorded during the three months ended March 31, 2006, \$2.0 million was recorded during the three months ended June 30, 2006, and \$1.8 million was recorded during the three months ended September 30, 2006. This loss contingency is included in other current liabilities as of September 30, 2006 in the accompanying condensed consolidated balance sheets, and is included in selling, general and administrative expenses for the nine months ended September 30, 2006 in the accompanying condensed consolidated statements of income.

On or about October 12, 2006, the Company and the United States Attorney's Office for the District of Kansas entered into a Nonprosecution Agreement wherein the government agreed not to prosecute the Company for any alleged criminal violations relating to the alleged off-label marketing and promotion of LOPROX®. In exchange for the government's agreement not to pursue any criminal charges against the Company, the Company has agreed to continue cooperating with the government in its ongoing investigation into whether past and present employees and officers may have violated federal criminal law regarding alleged off-label marketing and promotion of LOPROX® to pediatricians. No individuals have been designated as targets of the investigation. Any such claims, prosecutions or other proceedings, with respect to the Company's past and present employees and officers, the cost of their defense and fines and penalties resulting therefrom could have a material impact on the Company's reputation, business and financial condition.

**Table of Contents**

The Company also is engaged in discussions with the Office of Inspector General of the Department of Health and Human Services ( IG ) to resolve any potential administrative claims the IG may have arising out of the government s investigation into the Company s marketing and promotion of LOPROX®.

In addition to the matters discussed above, in the ordinary course of business, the Company is involved in a number of legal actions, both as plaintiff and defendant, and could incur uninsured liability in any one or more of them. Although the outcome of these actions is not presently determinable, it is the opinion of the Company s management, based upon the information available at this time, that the expected outcome of these matters, individually or in the aggregate, will not have a material adverse effect on the results of operations or financial condition of the Company.

**16. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS**

In June 2006, the FASB issued Interpretation No. 48 ( FIN 48 ) *Accounting for Uncertainty in Income Taxes*, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise s financial statements in accordance with FASB Statement No. 109, *Accounting for Income Taxes*. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006. The Company is currently evaluating FIN 48 but does not expect it to have a material impact on the Company s consolidated results of operations and financial condition.

In September 2006, the FASB issued SFAS No. 157, *Fair Value Measurements*, which clarifies the definition of fair value, establishes a framework for measuring fair value, and expands the disclosures about fair value measurements. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007. The Company is currently evaluating SFAS No. 157 and its impact, if any, on the Company s consolidated results of operations and financial condition.

**17. SUBSEQUENT EVENT**

On November 7, 2006, the FDA approved ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel for once daily use for the topical treatment of acne vulgaris in patients 12 years or older. The Company expects to begin selling ZIANA to wholesale customers during the fourth quarter of 2006. In accordance with the terms of a development and license agreement, as amended, with Dow Pharmaceutical Sciences, Inc. ( Dow ), the Company will pay Dow \$1.0 million during the fourth quarter of 2006 as a result of the FDA s approval of this product. The \$1.0 million payment will be classified as a long-lived asset in the Company s consolidated balance sheet.

**Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations**  
**Executive Summary**

We are a leading independent specialty pharmaceutical company focused primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the U.S. of products for the treatment of dermatological, aesthetic and podiatric conditions. We also market products in Canada for the treatment of dermatological and aesthetic conditions. We offer a broad range of products addressing various conditions or aesthetic improvements, including dermal fillers, acne, fungal infections, rosacea, hyperpigmentation, photoaging, psoriasis, skin and skin-structure infections, seborrheic dermatitis and cosmesis (improvement in the texture and appearance of skin).

Our current product lines are divided between the dermatological and non-dermatological fields. The dermatological field represents products for the treatment of acne and acne-related dermatological conditions and non-acne dermatological conditions. The non-dermatological field represents products for the treatment of urea cycle disorder and contract revenue. Our acne and acne-related dermatological product lines include DYNACIN®, PLEXION®, SOLODYN™ and TRIAZ®. Our non-acne dermatological product lines include LOPROX®, OMNICEF®, RESTYLANE® and VANOS™. Our non-

**Table of Contents**

dermatological product lines include AMMONUL® and BUPHENYL®. Our non-dermatological field also includes contract revenues associated with licensing agreements and authorized generic agreements.

*Key Aspects of Our Business*

We derive a majority of our revenue from our core products: OMNICEF®, RESTYLANE®, SOLODYN™, TRIAZ® and VANOS. We believe that sales of our core products, ZIANA, which was approved by the FDA on November 7, 2006, and PERLANE®, which is not currently approved for use by the FDA in the U.S., will constitute a significant portion of our sales for the foreseeable future.

We have built our business by executing a four-part growth strategy: promoting existing core brands, developing new products and important product line extensions, entering into strategic collaborations and acquiring complementary products, technologies and businesses. Our core philosophy is to cultivate relationships of trust and confidence with the high prescribing dermatologists and podiatrists and the leading plastic surgeons in the United States. We rely on third parties to manufacture our products.

As a result of customer buying patterns, a substantial portion of our prescription product revenues has been recognized in the last month of each quarter, and we schedule our inventory purchases to meet anticipated customer demand. As a result, miscalculation of customer demand or relatively small delays in our receipt of manufactured products could result in revenues being deferred or lost. Our operating expenses are based upon anticipated sales levels, and a high percentage of our operating expenses are relatively fixed in the short term. Depending on the customer, we recognize revenue at the time of shipment to the customer, or at the time of receipt by the customer, net of estimated provisions. Consequently, variations in the timing of revenue recognition could cause significant fluctuations in operating results from period to period and may result in unanticipated periodic earnings shortfalls or losses.

We estimate customer demand for our prescription products primarily through use of third party syndicated data sources which track prescriptions written by health care providers and dispensed by licensed pharmacies. The data represents extrapolations from information provided only by certain pharmacies and are estimates of historical demand levels. We estimate customer demand for our non-prescription products primarily through internal data that we compile. We observe trends from these data, and, coupled with certain proprietary information, prepare demand forecasts that are the basis for our purchase orders for finished and component inventory from our third party manufacturers and suppliers. Our forecasts may fail to accurately anticipate ultimate customer demand for products. Overestimates of demand may result in excessive inventory production and underestimates may result in inadequate supply of our products in channels of distribution.

We sell our products primarily to major wholesalers and retail pharmacy chains. Approximately 75% of our gross revenues are derived from two major drug wholesale concerns. While we attempt to estimate inventory levels of our products at our major wholesale customers by using historical prescription information and historical purchase patterns, this process is inherently imprecise. Rarely do wholesale customers provide us complete inventory levels at regional distribution centers, or within their national distribution systems. We rely wholly upon our wholesale and drug chain customers to effect the distribution allocation of substantially all of our products. Based upon historically consistent purchasing patterns of our major wholesale customers, we believe our estimates of trade inventory levels of our products are reasonable. We further believe that inventories of our products among wholesale customers, taken as a whole, are similar to those of other specialty pharmaceutical companies, and that our trade practices, which periodically involve volume discounts and early payment discounts, are typical of the industry.

We periodically offer promotions to wholesale and chain drugstore customers to encourage dispensing of our prescription products, consistent with prescriptions written by licensed health care providers. Because many of our prescription products compete in multi-source markets, it is important for us to ensure the licensed health care providers dispensing instructions are fulfilled with our branded products and are not substituted with a generic product or another therapeutic alternative product which may be contrary to the licensed health care providers recommended and prescribed Medicis brand. We believe that a critical component of our brand protection program is maintenance of full product

## Table of Contents

availability at drugstore and wholesale customers. We believe such availability reduces the probability of local and regional product substitutions, shortages and backorders, which could result in lost sales. We expect to continue providing favorable terms to wholesale and retail drug chain customers as may be necessary to ensure the fullest possible distribution of our branded products within the pharmaceutical chain of commerce.

We cannot control or significantly influence the purchasing patterns of our wholesale and retail drug chain customers. They are highly sophisticated customers that purchase products in a manner consistent with their industry practices and, presumably, based upon their projected demand levels. Purchases by any given customer, during any given period, may be above or below actual prescription volumes of any of our products during the same period, resulting in fluctuations of product inventory in the distribution channel.

### *Recent Developments*

The following significant events and transactions occurred during the nine months ended September 30, 2006 and affected our results of operations, our cash flows and our financial condition:

- Development and distribution agreement with Ipsen for rights to Ipsen's botulinum toxin product known as RELOXIN®;
- FDA approval of our New Drug Application for SOLODYN™;
- Loss contingency for a pending governmental investigation relating to our marketing and promotion of LOPROX® products; and
- Write-down of long-lived assets due to impairment.

### *Development and Distribution Agreement With Ipsen for Rights to Ipsen's Botulinum Toxin Product Known as RELOXIN®*

On March 17, 2006, we entered into a development and distribution agreement with Ipsen Ltd., a wholly-owned subsidiary of Ipsen S.A. ( Ipsen ), whereby Ipsen granted Aesthetica Ltd., a wholly-owned subsidiary of Medicis, rights to develop, distribute and commercialize Ipsen's botulinum toxin product in the United States, Canada and Japan for aesthetic use by physicians. The product is commonly referred to as RELOXIN® in the U.S. aesthetic market and DYSPORT® in medical and aesthetic markets outside the U.S. The product is not currently approved for use in the U.S., Canada or Japan. Upon execution of the development and distribution agreement, we made an initial payment to Ipsen in the amount of \$90.1 million in consideration for the exclusive distribution rights in the U.S., Canada and Japan.

Additionally, we agreed to negotiate and enter into an agreement relating to the exclusive distribution and development rights of the product for the aesthetic market in Europe, and subsequently in certain other markets. Under the terms of the U.S., Canada and Japan agreement, we were obligated to make an additional \$35.1 million payment, as amended, to Ipsen if this agreement was not entered into by April 15, 2006. On April 13, 2006, we agreed with Ipsen to extend this deadline to July 15, 2006. In connection with this extension, we paid Ipsen approximately \$12.9 million in April 2006, which would be applied against the total obligation, in the event an agreement was not entered into by the extended deadline. On July 17, 2006, we reached a decision with Ipsen to not pursue an agreement for the commercialization of the product outside of the U.S., Canada and Japan. On July 17, 2006, we made the additional \$22.2 million payment to Ipsen, representing the remaining portion of the \$35.1 million total obligation, resulting from the discontinuance of negotiations for other territories.

The initial \$90.1 million payment was recognized as a charge to research and development expense during the three months ended March 31, 2006, and the \$35.1 million obligation was recognized as a charge to research and development expense during the three months ended June 30, 2006.

We will pay an additional \$26.5 million upon successful completion of various clinical and regulatory milestones, \$75.0 million upon the product's approval by the FDA and \$2.0 million upon regulatory approval of the product in Japan. Ipsen will manufacture and provide the product to us for the term of the agreement, which extends to September 2019. Ipsen will receive a royalty based on sales and a supply price, the total of which is equivalent to approximately 30% of net sales as defined under the





**Table of Contents**

agreement. Under the terms of the agreement, we are responsible for all remaining research and development costs associated with obtaining the product's approval in the U.S., Canada and Japan. We expect to incur significant additional research and development expenses related to the development of RELOXIN® each quarter throughout the development process. It is our current expectation that we will file a Biologic License Application ( BLA ) for RELOXIN® with the FDA during calendar 2007.

*FDA approval of our New Drug Application for SOLODYN™*

On May 8, 2006, the FDA approved our New Drug Application for our SOLODYN™ (minocycline HCl, USP) Extended Release Tablets. SOLODYN™ is the only oral minocycline approved for once daily dosage in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older. SOLODYN™ is also the only approved minocycline in extended release tablet form. The first sales of SOLODYN™ to our wholesale customers occurred during June 2006.

*Loss contingency for a pending governmental investigation relating to our marketing and promotion of LOPROX® products*

The government notified us on December 14, 2004, that it is investigating claims that we violated the federal False Claims Act in connection with the alleged off-label marketing and promotion of LOPROX® and LOPROX® TS products ( LOPROX® ) to pediatricians during periods prior to our May 2004 disposition of the Company's pediatric sales division. In April 2006, we offered \$6.0 million to resolve the government's civil claims contingent on the execution of appropriate releases. The Justice Department countered with a demand of \$12.8 million to resolve the civil claims that the government is prepared to pursue. In May 2006, we countered with an offer of \$8.0 million that was contingent on resolving other aspects of the government's investigation to our satisfaction. In June 2006, the Justice Department countered with a \$10.0 million offer for settlement. On or about October 5, 2006 the parties agreed in principle to resolve all federal and state civil claims against the Company for \$9.8 million. Accordingly, we have accrued a loss contingency of \$9.8 million as of September 30, 2006, related to this matter, of which \$6.0 million was recorded during the three months ended March 31, 2006, \$2.0 million was recorded during the three months ended June 30, 2006 and \$1.8 million was recorded during the three months ended September 30, 2006.

On or about October 12, 2006, the Company and the United States Attorney's Office for the District of Kansas entered into a Nonprosecution Agreement wherein the government agreed not to prosecute the Company for any alleged criminal violations relating to the alleged off-label marketing and promotion of LOPROX®. In exchange for the government's agreement not to pursue any criminal charges against the Company, the Company has agreed to continue cooperating with the government in its ongoing investigation into whether past and present employees and officers may have violated federal criminal law regarding alleged off-label marketing and promotion of LOPROX® to pediatricians. No individuals have been designated as targets of the investigation. Any such claims, prosecutions or other proceedings, with respect to our past and present employees and officers, the cost of their defense and fines and penalties resulting therefrom could have a material impact on our reputation, business and financial condition.

The Company also is engaged in discussions with the Office of Inspector General of the Department of Health and Human Services ( IG ) to resolve any potential administrative claims the IG may have arising out of the government's investigation into the Company's marketing and promotion of LOPROX®.

**Table of Contents***Write-down of Long-lived Assets Due to Impairment*

We assess the potential impairment of long-lived assets on a periodic basis and when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Factors that we consider in deciding when to perform an impairment review include significant under-performance of a product line in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use of the assets. Recoverability of assets that will continue to be used in our operations is measured by comparing the carrying amount of the asset grouping to our estimate of the related total future net cash flows. If an asset carrying value is not recoverable through the related cash flows, the asset is considered to be impaired. The impairment is measured by the difference between the asset grouping's carrying amount and its fair value, based on the best information available, including market prices or discounted cash flow analysis.

During the quarter ended September 30, 2006, long-lived assets related to certain of our products were determined to be impaired based on our analysis of the long-lived assets' carrying value and projected future cash flows. As a result of the impairment analysis, we recorded a write-down of approximately \$52.5 million related to these long-lived assets. This write-down included the following (in thousands):

Long-lived asset related to LOPROX® products	\$ 49,163
Long-lived asset related to ESOTERICA® products	3,267
Other long-lived asset	156
	\$ 52,586

Factors affecting the future cash flows of the LOPROX® long-lived asset included competitive pressures in the marketplace and the cancellation of the development plan to support future forms of LOPROX®. Factors affecting the future cash flows of the ESOTERICA® long-lived asset included a notice of proposed rulemaking by the FDA for an NDA to be required for continued marketing of hydroquinone products, such as ESOTERICA®. ESOTERICA® is currently an over-the-counter product line, and we do not plan to invest in obtaining an approved NDA for this product line if this proposed rule is made final without change.

In addition, as a result of the impairment analysis, the remaining amortizable lives of the long-lived assets related to LOPROX® and ESOTERICA® were reduced to fifteen years and fifteen months, respectively. The long-lived asset related to LOPROX® will become fully amortized on September 30, 2021, and the long-lived asset related to ESOTERICA® will become fully amortized on December 31, 2007. The net impact on amortization expense as a result of the write-down of the carrying value of the long-lived assets and the reduction of their respective amortizable lives is a decrease in quarterly amortization expense related to LOPROX® of \$354,051 and an increase in quarterly amortization expense related to ESOTERICA® of \$48,077.

**Table of Contents**

## Results of Operations

The following table sets forth certain data as a percentage of net revenues for the periods indicated.

	<b>THREE MONTHS ENDED SEPTEMBER 30,</b>		<b>NINE MONTHS ENDED SEPTEMBER 30,</b>	
	<b>2006 (a)</b>	<b>2005 (b)</b>	<b>2006 (c)</b>	<b>2005 (d)</b>
Net revenues	100.0%	100.0%	100.0%	100.0%
Gross profit (e)	90.5	85.6	88.0	85.6
Operating expenses	134.5	63.5	150.3	55.5
Operating (loss) income	(44.0)	22.1	(62.3)	30.1
Interest and investment income, net	5.8	1.7	5.7	0.9
(Loss) income before income tax (benefit) expense	(38.2)	23.8	(56.6)	31.0
Income tax (benefit) expense	(15.2)	8.8	(19.1)	10.8
Net (loss) income	(23.0)%	15.0%	(37.5)%	20.2%

(a) Included in operating expenses is \$52.6 million (58.4% of net revenues) for the write-down of long-lived assets, \$6.6 million (7.4% of net revenues) of compensation expense related to stock options and restricted stock and \$1.8 million (2.0% of net revenues) related to a loss contingency for a legal matter.

(b) Included in operating expenses is \$7.7 million

(9.2% of net revenues) of compensation expense related to stock options and restricted stock and \$0.7 million (0.8% of net revenues) of business integration planning costs related to the proposed (and subsequently terminated) merger with Inamed.

- (c) Included in operating expenses is \$125.2 million (50.0% of net revenues) related to our development and distribution agreement with Ipsen for the development of RELOXIN®, \$52.6 million (21.0% of net revenues) for the write-down of long-lived assets, \$21.2 million (8.5% of net revenues) of compensation expense related to stock options and restricted stock, \$9.8 million (3.9% of net revenues) related to a loss

contingency for a legal matter and \$1.8 million (0.7% of net revenues) related to a settlement of a dispute related to our merger with Ascent.

- (d) Included in operating expenses is \$8.3 million (3.0% of net revenues) related to a research and development collaboration with AAIPharma, \$7.9 million (2.8% of net revenues) of compensation expense related to stock options and restricted stock, and \$6.0 million (2.7% of net revenues) of business integration planning costs related to the proposed (and subsequently terminated) merger with Inamed.
- (e) Gross profit does not include amortization of the related intangibles as such expenses are included in

operating  
expenses.

*Three Months Ended September 30, 2006 Compared to the Three Months Ended September 30, 2005*

*Net Revenues*

The following table sets forth the net revenues for the three months ended September 30, 2006 (the third quarter of 2006 ) and September 30, 2005 (the third quarter of 2005 ), along with the percentage of net revenues and percentage point change for each of our product categories (dollar amounts in millions):

	Third Quarter 2006	Third Quarter 2005	\$ Change	% Change
Net product revenues	\$ 86.2	\$ 79.4	\$ 6.8	8.6%
Net contract revenues	3.8	3.9	( 0.1)	(1.8)
Net revenues	\$ 90.0	\$ 83.3	\$ 6.7	8.1%

  

	Third Quarter 2006	Third Quarter 2005	Percentage Point Change
Acne and acne-related dermatological products	47.3%	32.6%	14.7%
Non-acne dermatological products	45.5	56.2	(10.7)
Non-dermatological products	7.2	11.2	(4.0)
Total net revenues	100.0%	100.0%	

**Table of Contents**

Our total net revenues increased approximately \$6.7 million, or 8.1%, to \$90.0 million during the third quarter of 2006 from \$83.3 million during the third quarter of 2005. Core brand revenues, which includes revenues associated with OMNICEF®, RESTYLANE®, SOLODYN, TRIAZ® and VANOS, were \$82.7 million during the third quarter of 2006, an increase of approximately 15.2%, compared to core brand revenues of \$71.8 million for the third quarter of 2005. Core brand revenues for the third quarter of 2005 also included revenues associated with DYNACIN®, LOPROX® and PLEXION®. Net revenues associated with our acne and acne-related dermatological products increased as a percentage of net revenues and increased in net revenue dollars by 57.0% during the third quarter of 2006 as compared to the third quarter of 2005, primarily due to sales of SOLODYN, which was approved by the FDA during the second quarter of 2006, which were partially offset by decreases in sales of DYNACIN®, PLEXION® and TRIAZ® products due to competitive pressures, including generic competition. Net revenues associated with our non-acne dermatological products decreased as a percentage of net revenues and decreased in net revenue dollars by 12.5% during the third quarter of 2006, as compared to the third quarter of 2005. This change included an increase in sales of RESTYLANE®, offset by a decrease in sales of LOPROX® products due to competitive pressures, including generic competition. Net revenues associated with our non-dermatological products decreased as a percentage of net revenues and decreased in net revenue dollars by 31.0% during the third quarter of 2006 as compared to the third quarter of 2005, primarily due to a decrease in net revenues of AMMONUL®.

*Gross Profit*

Gross profit represents our net revenues less our cost of product revenue. Our cost of product revenue includes our cost for the products we purchase from our third party manufacturers and royalty payments made to third parties. Amortization of intangible assets related to acquired products is not included in gross profit. Product mix plays a significant role in our quarterly and annual gross profit as a percentage of net revenues. Different products generate different gross profit margins, and the relative sales mix of higher gross profit products and lower gross profit products can affect our total gross profit.

The following table sets forth our gross profit for the third quarter of 2006 and 2005, along with the percentage of net revenues represented by such gross profit (dollar amounts in millions):

	Third Quarter 2006	Third Quarter 2005	\$Change	% Change
Gross profit	\$81.5	\$71.2	\$10.3	14.4%
% of net revenues	90.5%	85.6%		

The increase in gross profit dollars during the third quarter of 2006, compared to the third quarter of 2005, was due to the increase in our net revenues and gross profit impact of the mix of products sold during the comparable quarters. The increase in gross profit as a percentage of net revenues was primarily due to the different mix of high gross margin products sold during the third quarter of 2006 as compared to the third quarter of 2005. The launch of SOLODYN during the second quarter of 2006, a higher margin product, was the primary change in the mix of products sold during the comparable periods that affected gross profit as a percentage of net revenues.



**Table of Contents***Selling, General and Administrative Expenses*

The following table sets forth our selling, general and administrative expenses for the third quarter of 2006 and 2005, along with the percentage of net revenues represented by selling, general and administrative expenses (dollar amounts in millions):

	Third Quarter	Third Quarter	\$	%
	2006	2005	Change	Change
Selling, general and administrative % of net revenues	\$ 53.6 59.6%	\$ 41.5 49.8%	\$ 12.1	29.3%
Inamed business integration planning costs included in selling, general and administrative	\$	\$ 0.7	\$ (0.7)	(100.0)%
Share-based compensation expense included in selling, general and administrative	\$ 6.2	\$ 7.2	\$ (1.0)	(14.0)%

The increase in selling, general and administrative expenses during the third quarter of 2006 from the third quarter of 2005 was attributable to \$5.3 million of increased promotion expense primarily related to the promotion of RESTYLANE®, the launch of SOLODYN and pre-launch costs for PERLANE®, \$1.8 million related to a loss contingency for a legal matter related to our marketing of LOPROX® to pediatricians (see Part II, Item 1, Legal Proceedings), \$2.4 million of increased personnel costs due to increased headcount and the effect of the annual salary increase that occurred during August 2005 the partial-year salary increase that occurred during February 2006, and \$4.3 million of other additional selling, general and administrative expenses incurred during the third quarter of 2006, which was partially offset by a \$1.0 million decrease in share-based compensation expense and \$0.7 million of business integration planning costs related to the proposed (and subsequently terminated) merger with Inamed Corporation incurred during the third quarter of 2005. We expect marketing and personnel expenses to continue to be higher than in comparable periods, due to our preparation for the potential launch of PERLANE®, additional promotional costs related to RESTYLANE®, and expansion of our aesthetics sales force.

*Impairment of Long-lived Assets*

During the third quarter of 2006, long-lived assets related to certain of our products were determined to be impaired based on our analysis of the long-lived assets carrying value and projected future cash flows. As a result of the impairment analysis, we recorded a write-down of approximately \$52.6 million related to these long-lived assets. This write-down included the following (in thousands):

Long-lived asset related to LOPROX® products	\$ 49,163
Long-lived asset related to ESOTERICA® products	3,267
Other long-lived asset	156
	\$ 52,586

Factors affecting the future cash flows of the LOPROX® long-lived asset included competitive pressures in the marketplace and the cancellation of the development plan to support future forms of LOPROX®. Factors affecting the future cash flows of the ESOTERICA® long-lived asset included a notice of proposed rulemaking by the FDA for an NDA to be required for continued marketing of hydroquinone products, such as ESOTERICA®. ESOTERICA® is currently an over-the-counter product line, and we do not plan to invest in obtaining an approved NDA for this product line if this proposed rule is made final without change.

**Table of Contents***Research and Development Expenses*

The following table sets forth our research and development expenses for the third quarter of 2006 and 2005 (dollar amounts in millions):

	Third Quarter 2006	Third Quarter 2005	\$ Change	% Change
Research and development	\$9.0	\$5.1	\$3.9	77.8%
Share-based compensation expense included in research and development	\$0.5	\$0.5	\$	%

The increase in research and development expenses during the third quarter of 2006 from the third quarter of 2005 was primarily due to costs related to the development of RELOXIN<sup>®</sup>. We expect research and development expenses to continue to fluctuate from quarter to quarter based on the timing of the achievement of development milestones under license and development agreements, as well as the timing of other development projects and the funds available to support these projects. We expect to continue to incur significant research and development expenses related to the development of RELOXIN<sup>®</sup> each quarter throughout the development process.

*Depreciation and Amortization Expenses*

Depreciation and amortization expenses during the third quarter of 2006 decreased \$0.4 million, or 7.2%, to \$5.9 million from \$6.3 million during the third quarter of 2005. This decrease was primarily due to a decrease in the amount of intangible assets being amortized during the third quarter of 2006 as compared to the third quarter of 2005, due to the write-down of a long-lived asset due to impairment during the three months ended December 31, 2005. This long-lived asset had a cost basis of approximately \$15.4 million and was being amortized at a rate of approximately \$0.3 million per quarter.

*Interest and Investment Income*

Interest and investment income during the third quarter of 2006 increased \$3.8 million, or 92.6%, to \$7.9 million from \$4.1 million during the third quarter of 2005, due to an increase in the funds available for investment and an increase in the interest rates achieved by our invested funds during the third quarter of 2006.

*Interest Expense*

Interest expense during the third quarter of 2006 remained consistent with the third quarter of 2005, at \$2.7 million. Our interest expense during the third quarter of 2006 and 2005 consisted of interest expense on our Old Notes, which accrue interest at 2.5% per annum, our New Notes, which accrue interest at 1.5% per annum, and amortization of fees and other origination costs related to the issuance of the Old Notes and New Notes. See Note 10 in our accompanying condensed consolidated financial statements for further discussion on the Old Notes and New Notes.

*Income Tax Expense*

The following table sets forth our income tax expense and the resulting effective tax rate stated as a percentage of pre-tax income for the third quarter of 2006 and 2005 (dollar amounts in millions):

	Third Quarter 2006	Third Quarter 2005	\$ Change	% Change
Income tax (benefit) expense	\$(13.7)	\$ 7.4	\$(21.1)	(285.0)%
Effective tax rate	(39.8)%	37.2%		

Income taxes are determined using an annual effective tax rate, which generally differs from the U.S. Federal statutory rate, primarily because of state and local income taxes, charitable contribution

**Table of Contents**

deductions, tax credits available in the U.S., the treatment of certain share-based payments under SFAS 123R that are not designed to normally result in tax deductions, and differences in tax rates in certain non-U.S. jurisdictions. Our effective tax rate may be subject to fluctuations during the year as new information is obtained which may affect the assumptions we use to estimate our annual effective tax rate, including factors such as our mix of pre-tax earnings in the various tax jurisdictions in which we operate, changes in valuation allowances against deferred tax assets, reserves for tax audit issues and settlements, utilization of tax credits and changes in tax laws in jurisdictions where we conduct operations. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating losses and credit carryforwards. We record valuation allowances against our deferred tax assets to reduce the net carrying values to amounts that management believes is more likely than not to be realized.

Our effective tax rate for the three months ended September 30, 2006 was (39.8)% compared to our effective tax rate of 37.2% for the three months ended September 30, 2005. Generally, the provision for income taxes reflects management's estimate of the effective tax rate expected to be applicable for the full fiscal year. However, during the three months ended September 30, 2006, the Company's effective tax rate of (39.8%) differs from the Company's estimate of the annual effective tax rate due to tax benefits from the impairment of long-lived assets charge being able to offset a greater amount of the non-deductible items.

*Nine Months Ended September 30, 2006 Compared to the Nine Months Ended September 30, 2005**Net Revenues*

The following table sets forth the net revenues for the nine months ended September 30, 2006 (the 2006 nine months) and September 30, 2005 (the 2005 nine months), along with the percentage of net revenues and percentage point change for each of our product categories (dollar amounts in millions):

	2006 Nine Months	2005 Nine Months	\$ Change	% Change
Net product revenues	\$ 237.9	\$ 237.5	\$ 0.4	0.2%
Net contract revenues	12.3	41.5	(29.2)	(70.5)
Net revenues	\$ 250.2	\$ 279.0	\$ (28.8)	(10.3)%

	2006 Nine Months	2005 Nine Months	Percentage Point Change
Acne and acne-related dermatological products	37.3%	28.3%	9.0%
Non-acne dermatological products	52.7	51.6	1.1
Non-dermatological products	10.0	20.1	(10.1)
Total net revenues	100.0%	100.0%	

Our total net revenues decreased during the 2006 nine months, compared to the 2005 nine months, primarily due to a decrease in net contract revenues associated with licensing agreements and authorized generic agreements. Net contract revenues decreased primarily due to a decrease in contract revenues during the 2006 nine months related to our outlicensing of the ORAPRED® brand pursuant to the terms of our license agreement with BioMarin. Core brand revenues, which are included in net product revenues and includes revenues associated with DYNACIN®, LOPROX®, OMNICEF®, PLEXION®, RESTYLANE®, SOLODYN, TRIAZ® and VANOS, were \$223.8 million during the 2006 nine months, an increase of approximately 2.8%, compared to core brand revenues of \$217.8 million for the 2005 nine

months. Net revenues for DYNACIN<sup>®</sup>, LOPROX<sup>®</sup> and PLEXION<sup>®</sup> are included in core brand revenues only through June 30, 2006. Net revenues associated with our acne and acne-related dermatological products increased as a percentage of net revenues, and increased in net revenue dollars by 18.2% during the 2006 nine months as compared to the 2005 nine months, primarily due to sales of SOLODYN, which was approved by the FDA during the

**Table of Contents**

second quarter of 2006, which were partially offset by decreases in sales of DYNACIN<sup>®</sup>, PLEXION<sup>®</sup> and TRIAZ<sup>®</sup> products due to competitive pressures, including generic competition. Net revenues associated with our non-acne dermatological products increased as a percentage of net revenues, but decreased in net revenue dollars by 8.3% during the 2006 nine months, primarily due to an increase in sales of RESTYLANE<sup>®</sup>, which was partially offset by decreases in sales of VANOS and LOPROX<sup>®</sup> products. Net revenues associated with our non-dermatological products decreased as a percentage of net revenues, and decreased in net revenue dollars by 55.5% during the 2006 nine months, primarily due to the decrease in ORAPRED<sup>®</sup> contract revenues discussed above.

*Gross Profit*

The following table sets forth our gross profit for the 2006 nine months and the 2005 nine months, along with the percentage of net revenues represented by such gross profit (dollar amounts in millions):

	2006 Nine Months	2005 Nine Months	\$ Change	% Change
Gross profit	\$220.1	\$238.8	\$(18.7)	(7.8)%
% of net revenues	88.0%	85.6%		

The decrease in gross profit dollars during the 2006 nine months, compared to the 2005 nine months, was due to the decrease in our net revenues. The increase in gross profit as a percentage of net revenues was primarily due to the different mix of high gross margin products sold during the 2006 nine months as compared to the 2005 nine months. The launch of SOLODYN during the second quarter of 2006, a higher margin product, was the primary change in the mix of products sold during the comparable periods that affected gross profit as a percentage of net revenues.

*Selling, General and Administrative Expenses*

The following table sets forth our selling, general and administrative expenses for the 2006 nine months and 2005 nine months, along with the percentage of net revenues represented by selling, general and administrative expenses (dollar amounts in millions):

	2006 Nine Months	2005 Nine Months	\$ Change	% Change
Selling, general and administrative	\$155.9	\$110.9	\$45.0	40.6%
% of net revenues	62.2%	39.8%		
Inamed business integration planning costs included in selling, general and administrative	\$	\$ 6.0	\$(6.0)	(100.0)%
Share-based compensation expense included in selling, general and administrative	\$ 19.7	\$ 7.4	\$12.3	164.2%

The increase in selling, general and administrative expenses during the 2006 nine months from the 2005 nine months was attributable to approximately \$12.3 million of additional share-based compensation expense recognized in accordance with SFAS No. 123R, \$9.8 million related to a loss contingency for a legal matter related to our marketing of LOPROX<sup>®</sup> to pediatricians (see Part II, Item 1, Legal Proceedings), approximately \$8.4 million of increased promotional expense, primarily related to the promotion of RESTYLANE<sup>®</sup>, the launch of SOLODYN and pre-launch costs for PERLANE<sup>®</sup>, \$6.2 million of increased personnel costs due to increased headcount and the effect of the annual salary increase that occurred during August 2005 and the partial-year salary increase that occurred during February 2006, \$1.8 million related to a settlement of a dispute related to our merger with Ascent, and \$12.5 million of other additional selling, general and administrative expenses incurred during the 2006 nine months, which was partially offset by \$6.0 million of business integration planning costs related to the proposed (and subsequently terminated) merger with Inamed incurred during the 2005 nine months.

*Impairment of Long-lived Assets*

During the third quarter of 2006, long-lived assets related to certain of our products were determined to be impaired based on our analysis of the long-lived assets carrying value and projected

**Table of Contents**

future cash flows. As a result of the impairment analysis, we recorded a write-down of approximately \$52.6 million related to these long-lived assets. This write-down included the following (in thousands):

Long-lived asset related to LOPROX® products	\$ 49,163
Long-lived asset related to ESOTERICA® products	3,267
Other long-lived asset	156
	\$ 52,586

Factors affecting the future cash flows of the LOPROX® long-lived asset included competitive pressures in the marketplace and the cancellation of the development plan to support future forms of LOPROX®. Factors affecting the future cash flows of the ESOTERICA® long-lived asset included a notice of proposed rulemaking by the FDA for an NDA to be required for continued marketing of hydroquinone products, such as ESOTERICA®. ESOTERICA® is currently an over-the-counter product line, and we do not plan to invest in obtaining an approved NDA for this product line if this proposed rule is made final without change.

*Research and Development Expenses*

The following table sets forth our research and development expenses for the 2006 nine months and 2005 nine months (dollar amounts in millions):

	2006 Nine Months	2005 Nine Months	\$ Change	% Change
Research and development	\$ 150.0	\$ 25.6	\$ 124.4	486.0%
Charges included in research and development	\$ 125.2	\$ 8.3	\$ 116.9	1,412.0%
Share-based compensation expense included in research and development	\$ 1.5	\$ 0.5	\$ 1.0	195.8%

Included in research and development expenses for the 2006 nine months was \$125.2 million related to the development and distribution agreement with Ipsen for the development of RELOXIN® and approximately \$1.5 million of compensation expense for stock options and restricted stock. Included in research and development expense for the 2005 nine months was approximately \$8.3 million related to a research and development collaboration with AAIPharma and approximately \$0.5 million of compensation expense for stock options and restricted stock. In addition to these increases in development milestone charges and share-based compensation expense, research and development expenses increased due to costs related to the development of RELOXIN® incurred during the 2006 nine months. We expect research and development expenses to continue to fluctuate from quarter to quarter based on the timing of the achievement of development milestones under license and development agreements, as well as the timing of other development projects and the funds available to support these projects. We expect to incur significant research and development expenses related to the development of RELOXIN® each quarter throughout the development process.

*Depreciation and Amortization Expenses*

Depreciation and amortization expenses during the 2006 nine months decreased \$0.9 million, or 5.0%, to \$17.5 million from \$18.4 million during the 2005 nine months. This decrease was primarily due to a decrease in the amount of intangible assets being amortized during the 2006 nine months as compared to the 2005 nine months, due to the write-down of a long-lived asset due to impairment during the three months ended December 31, 2005. This long-lived asset had a cost basis of approximately \$15.4 million and was being amortized at a rate of approximately \$0.3 million per quarter.

*Interest and Investment Income*

Interest and investment income during the 2006 nine months increased \$11.7 million, or 111.3%, to \$22.2 million from \$10.5 million during the 2005 nine months, due to an increase in the funds available for investment and an increase in the interest rates achieved by our invested funds during the 2006 nine months.



**Table of Contents***Interest Expense*

Interest expense during the 2006 nine months remained consistent with the 2005 nine months, at \$8.0 million. Our interest expense during the 2006 nine months and 2005 nine months consisted of interest expense on our Old Notes, which accrue interest at 2.5% per annum, our New Notes, which accrue interest at 1.5% per annum, and amortization of fees and other origination costs related to the issuance of the Old Notes and New Notes. See Note 10 in our accompanying condensed consolidated financial statements for further discussion on the Old Notes and New Notes.

*Income Tax Expense*

The following table sets forth our income tax expense and the resulting effective tax rate stated as a percentage of pre-tax income for the 2006 nine months and 2005 nine months (dollar amounts in millions):

	2006 Nine Months	2005 Nine Months	\$ Change	% Change
Income tax (benefit) expense	\$(48.0)	\$30.2	\$(78.2)	(259.1)%
Effective tax rate	(33.9)%	34.9%		

Income taxes are determined using an annual effective tax rate, which generally differs from the U.S. Federal statutory rate, primarily because of state and local income taxes, charitable contribution deductions, tax credits available in the U.S., the treatment of certain share-based payments under SFAS 123R that are not designed to normally result in tax deductions, and differences in tax rates in certain non-U.S. jurisdictions. Our effective tax rate may be subject to fluctuations during the year as new information is obtained which may affect the assumptions we use to estimate our annual effective tax rate, including factors such as our mix of pre-tax earnings in the various tax jurisdictions in which we operate, changes in valuation allowances against deferred tax assets, reserves for tax audit issues and settlements, utilization of tax credits and changes in tax laws in jurisdictions where we conduct operations. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating losses and credit carryforwards. We record valuation allowances against our deferred tax assets to reduce the net carrying values to amounts that management believes is more likely than not to be realized.

Our effective tax rate for the 2006 nine months was (33.9)% compared to our effective tax rate of 34.9% for the 2005 nine months. The provision for income taxes reflects management's estimate of the effective tax rate expected to be applicable for the full fiscal year. Our effective tax rate of (33.9)% is consistent with our estimate of the effective tax rate for the full fiscal year of (34%)-(35%). The current estimate of the annual effective tax rate includes a \$5.1 million tax benefit recorded during the second quarter of 2006 relating to resolutions of income tax examinations through years ended June 30, 2004. Our current estimate of the annual effective tax rate absent this \$5.1 million tax benefit is approximately (30%) (31%).



**Table of Contents**

## Liquidity and Capital Resources

*Overview*

The following table highlights selected cash flow components for the 2006 nine months and 2005 nine months, and selected balance sheet components as of September 30, 2006 and December 31, 2005 (dollar amounts in millions):

	2006 Nine Months	2005 Nine Months	\$ Change	% Change
Cash provided by (used in):				
Operating activities	\$ ( 74.7)	\$ 112.6	\$(187.3)	(166.4)%
Investing activities	\$(269.8)	\$ 110.0	\$(379.8)	(345.2)%
Financing activities	\$ 5.2	\$ (3.8)	\$ 9.0	(235.8)%
	Sept. 30, 2006	Dec. 31, 2005	\$ Change	% Change
Cash, cash equivalents and short-term investments	\$ 578.3	\$ 742.5	\$(164.3)	(22.1)%
Working capital	\$ 575.4	\$ 692.5	\$(117.0)	(16.9)%
Long-term investments	\$ 65.7		\$ 65.7	100.0%
2.5% contingent convertible senior notes due 2032	\$ 169.2	\$ 169.2	\$	
1.5% contingent convertible senior notes due 2033	\$ 283.9	\$ 283.9	\$	

*Working Capital*

Working capital as of September 30, 2006 and December 31, 2005 consisted of the following (dollar amounts in millions):

	Sept. 30, 2006	Dec. 31, 2005	\$ Change	% Change
Cash, cash equivalents and short-term investments	\$ 578.3	\$ 742.5	\$ (164.2)	(22.1)%
Accounts receivable, net	21.0	46.7	(25.7)	(55.1)%
Inventories, net	20.1	19.1	1.0	5.3%
Deferred tax assets, net	16.7	12.7	4.0	31.1%
Other current assets	17.5	12.3	5.2	44.0%
Total current assets	653.6	833.3	(179.7)	(21.6)%
Accounts payable	27.6	57.7	(30.1)	(52.2)%
Short-term contract obligation		27.4	(27.4)	(100.0)%
Income taxes payable	8.9	31.5	(22.6)	(71.8)%
Other current liabilities	41.7	24.2	17.5	72.5%
Total current liabilities	78.2	140.8	(62.6)	(44.5)%
Working capital	\$ 575.4	\$ 692.5	\$ (117.1)	(16.9)%

We had cash, cash equivalents and short-term investments of \$578.3 million and working capital of \$575.4 million at September 30, 2006, as compared to \$742.5 million and \$692.5 million, respectively, at December 31, 2005. The

decreases were primarily due to payments totaling \$125.2 million made to Ipsen related to a development and distribution agreement for the development of RELOXIN<sup>®</sup>, payment of the \$27.4 million contingent payment related to the merger with Ascent, and payments totaling \$29.8 million for income taxes during the 2006 nine months. In addition, approximately \$65.7 million of our available-for-sale investments have been treated as long-term assets as of September 30, 2006, based on their expected maturities.

Accounts payable decreased from \$57.7 million at December 31, 2005 to \$27.6 million at September 30, 2006 primarily due to the payment of \$16.7 million of professional fees related to the termination of the proposed merger with Inamed Corporation and a \$4.0 million development milestone

**Table of Contents**

payment related to a research and development agreement, which were included in accounts payable as of December 31, 2005.

Management believes existing cash and short-term investments, together with funds generated from operations, should be sufficient to meet operating requirements for the foreseeable future. Our cash and short-term investments are available for strategic investments, mergers and acquisitions, and other potential large-scale needs. In addition, we may consider incurring additional indebtedness and issuing additional debt or equity securities in the future to fund potential acquisitions or investments, to refinance existing debt or for general corporate purposes. If a material acquisition or investment is completed, our operating results and financial condition could change materially in future periods. However, no assurance can be given that additional funds will be available on satisfactory terms, or at all, to fund such activities.

During July 2006, we completed a lease agreement for new headquarter office space to accommodate our expected long-term growth. The first phase is for approximately 150,000 square feet with the right to expand. Occupancy of the new headquarter office space, which is located approximately one mile from our current headquarter office space in Scottsdale, Arizona, is expected to occur in 2008.

*Operating Activities*

Net cash used in operating activities during the 2006 nine months was approximately \$74.7 million, compared to cash provided by operating activities of approximately \$112.6 million during the 2005 nine months. The following is a summary of the primary components of cash (used in) provided by operating activities during the 2006 nine months and 2005 nine months (in millions):

	2006 Nine Months	2005 Nine Months
Payments made to Ipsen related to development of RELOXIN®	\$ (125.2)	\$
Payment made to AAIPharma related to a research and development collaboration		(8.3)
Payment of professional fees related to termination of proposed merger with Inamed	(16.7)	
Income taxes paid	(29.8)	(15.9)
Other cash provided by operating activities	97.0	136.8
Cash (used in) provided by operating activities	\$ (74.7)	\$ 112.6

*Investing Activities*

Net cash used in investing activities during the 2006 nine months was approximately \$269.8 million, compared to net cash provided by investing activities during the 2005 nine months of \$110.0 million. The change was primarily due to the net purchases or sales of our short-term investments during the respective nine-month periods. In addition, approximately \$27.4 million was paid during the first quarter of 2006 for Contingent Payments related to our 2001 merger with Ascent.

*Financing Activities*

Net cash provided by financing activities during the 2006 nine months was \$5.2 million, compared to net cash used in financing activities of \$3.8 million during the 2005 nine months. Proceeds from the exercise of stock options were \$9.2 million during the 2006 nine months compared to \$1.0 million during the 2005 nine months. Dividends paid during the 2006 nine months and the 2005 nine months was \$4.9 million.

*Contingent Convertible Senior Notes and Other Long-Term Commitments*

On August 14, 2003, we exchanged \$230.8 million in principal amount of our Old Notes for \$283.9 million in principal amount of our New Notes. Holders of Old Notes that accepted the Company's exchange offer received \$1,230 in principal amount of New Notes for each \$1,000 in principal amount of Old Notes. The terms of the New Notes are similar to the terms of the Old Notes, but have a different

**Table of Contents**

interest rate, conversion rate and maturity date. Holders of Old Notes that did not exchange will continue to be subject to the terms of the Old Notes. See Note 10 of Notes to Condensed Consolidated Financial Statements for further discussion.

The New Notes and the Old Notes are unsecured and do not contain any restrictions on the incurrence of additional indebtedness or the repurchase of our securities, and do not contain any financial covenants. The Old Notes do not contain any restrictions on the payment of dividends. The New Notes require an adjustment to the conversion price if the cumulative aggregate of all current and prior dividend increases above \$0.025 per share would result in at least a one percent (1%) increase in the conversion price. This threshold has not been reached and no adjustment to the conversion price has been made.

Except for the Old Notes and the New Notes, we have no long-term liabilities and had only \$75.7 million of current liabilities at September 30, 2006. Our other commitments and planned expenditures consist principally of payments we will make in connection with strategic collaborations and research and development expenditures, and we will continue to invest in sales and marketing infrastructure. In addition, we will be implementing a new ERP system during 2007 and 2008, which will require financial expenditures to complete.

We have made available to BioMarin the ability to draw down on a Convertible Note up to \$25.0 million beginning July 1, 2005 (the Convertible Note). The Convertible Note is convertible based on certain terms and conditions including a change of control provision. Money advanced under the Convertible Note is convertible into BioMarin shares at a strike price equal to the BioMarin average closing price for the 20 trading days prior to such advance. The Convertible Note matures on the option purchase date in 2009 as defined in the securities purchase agreement entered into on May 18, 2004 but may be repaid by BioMarin at any time prior to the option purchase date. As of November 8, 2006, BioMarin has not requested any monies to be advanced under the Convertible Note, and no amounts are outstanding.

*Dividends*

We do not have a dividend policy. Since July 2003, we have paid quarterly cash dividends aggregating approximately \$20.1 million on our common stock. In addition, on September 14, 2006, we declared a cash dividend of \$0.03 per issued and outstanding share of common stock payable on October 31, 2006 to our stockholders of record at the close of business on October 2, 2006. Prior to these dividends, we had not paid a cash dividend on our common stock. Any future determinations to pay cash dividends will be at the discretion of our Board of Directors and will be dependent upon our financial condition, operating results, capital requirements and other factors that our Board of Directors deems relevant.

*Line of Credit*

We have a revolving line of credit facility of up to \$25.0 million from Wells Fargo Bank, N.A. The facility may be drawn upon by us, at our discretion, and is collateralized by certain short-term investments. Any outstanding balance of the credit facility bears interest at a floating rate of 150 basis points in excess of the 30-day London Interbank Offered Rate and expires in November 2006. The agreement requires us to comply with certain covenants, including covenants relating to our financial condition and results of operation; we are in compliance with such covenants. We have never drawn on this credit facility, and we do not intend to renew this line of credit facility after it expires in November 2006.

*Off-Balance Sheet Arrangements*

As of September 30, 2006, we are not involved in any off-balance sheet arrangements, as defined in Item 3(a)(4)(ii) of Securities and Exchange Commission (SEC) Regulation S-K.

*Critical Accounting Policies and Estimates*

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles. The preparation of the condensed consolidated financial statements requires us

**Table of Contents**

to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates related to sales allowances, chargebacks, rebates, returns and other pricing adjustments, depreciation and amortization and other contingencies and litigation. We base our estimates on historical experience and various other factors related to each circumstance. Actual results could differ from those estimates based upon future events, which could include, among other risks, changes in the regulations governing the manner in which we sell our products, changes in the health care environment and managed care consumption patterns. Our significant accounting policies are described in Note 2 to the consolidated financial statements included in our Form 10-K/T for the six-month transition period ended December 31, 2005. We believe the following critical accounting policies affect our most significant estimates and assumptions used in the preparation of our condensed consolidated financial statements and are important in understanding our financial condition and results of operations.

*Revenue Recognition*

Revenue from our product sales is recognized pursuant to Staff Accounting Bulletin No. 104 (SAB 104), Revenue Recognition in Financial Statements. Accordingly, revenue is recognized when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery of the products has occurred; (iii) the selling price is both fixed and determinable; and (iv) collectibility is reasonably assured. Our customers consist primarily of large pharmaceutical wholesalers who sell directly into the retail channel.

We do not provide any material forms of price protection to our wholesale customers and permit product returns if the product is damaged, or, depending on the customer, if it is returned within six months prior to expiration or up to 12 months after expiration. Our customers consist principally of financially viable wholesalers, and depending on the customer, revenue is recognized based upon shipment ( FOB shipping point ) or receipt ( FOB destination ), net of estimated provisions.

We enter into licensing arrangements with other parties whereby we receive contract revenue based on the terms of the agreement. The timing of revenue recognition is dependent on the level of our continuing involvement in the manufacture and delivery of licensed products. If we have continuing involvement, the revenue is deferred and recognized on a straight-line basis over the period of continuing involvement. In addition, if our licensing arrangements require no continuing involvement and payments are merely based on the passage of time, we assess such payments for revenue recognition under the collectibility criteria of SAB 104.

*Items Deducted From Gross Revenue*

Provisions for estimates for product returns and exchanges, sales discounts, chargebacks, managed care and Medicaid rebates and other adjustments are established as a reduction of product sales revenues at the time such revenues are recognized. These deductions from gross revenue are established by us as our best estimate at the time of sale based on historical experience adjusted to reflect known changes in the factors that impact such reserves. These deductions from gross revenue are generally reflected either as a direct reduction to accounts receivable through an allowance, or as an addition to accrued expenses if the payment is due to a party other than the wholesale or retail customer.

Our accounting policies for revenue recognition have a significant impact on our reported results and rely on certain estimates that require complex and subjective judgment on the part of our management. If the levels of product returns and exchanges, cash discounts, chargebacks, managed care and Medicaid rebates and other adjustments fluctuate significantly and/or if our estimates do not adequately reserve for these reductions of gross product revenues, our reported net product revenues could be negatively affected.

*Product Returns*

We account for returns of product by establishing an allowance based on our estimate of revenues recorded for which the related products are expected to be returned in the future. We determine our estimate of product returns based on historical experience and other qualitative factors that could impact the level of future product returns. These factors include estimated shelf life, competitive developments including introductions of generic products, product discontinuations and our introduction of new

**Table of Contents**

formulations of our products. Typically, these other factors that influence our allowance for product returns do not change significantly from quarter to quarter. Historical experience and the other qualitative factors are assessed on a product-specific basis as part of our compilation of our estimate of future product returns. Estimates for returns of new products are based on historical experience of new products at various stages of their life cycle.

Our actual experience and the qualitative factors that we use to determine the necessary allowance for future product returns are susceptible to change based on unforeseen events and uncertainties. We review our allowance for product returns quarterly to assess the trends being considered to estimate the allowance, and make changes to the allowance as necessary.

*Sales Discounts*

We offer cash discounts to our customers as an incentive for prompt payment, generally approximately 2% of the sales price. We account for cash discounts by establishing an allowance reducing accounts receivable by the full amount of the discounts expected to be taken by the customers.

*Contract Chargebacks*

We have agreements for contract pricing with several entities, whereby pricing on products is extended below wholesaler list price. These parties purchase products through wholesalers at the lower contract price, and the wholesalers charge the difference between their acquisition cost and the lower contract price back to us. We account for chargebacks by establishing an allowance reducing accounts receivable based on our estimate of chargeback claims attributable to a sale. We determine our estimate of chargebacks based on historical experience and changes to current contract prices. We also consider our claim processing lag time, and adjust the allowance periodically throughout each quarter to reflect actual experience.

*Managed Care and Medicaid Rebates*

We establish and maintain reserves for amounts payable by us to managed care organizations and state Medicaid programs for the reimbursement of portions of the retail price of prescriptions filled that are covered by these programs. The amounts estimated to be paid relating to products sold are recognized as deductions from gross revenue and as additions to accrued expenses at the time of sale based on our best estimate of the expected prescription fill rate to these managed care and state Medicaid patients, using historical experience adjusted to reflect known changes in the factors that impact such reserves, including changes in formulary status and contractual pricing.

*Other*

In addition to the significant items deducted from gross revenue described above, we deduct other items from gross revenue. For example, we offer consumer rebates on many of our products and a consumer loyalty program for our RESTYLANE® dermal filler product. We generally account for these other items deducted from gross revenue by establishing an accrual based on our estimate of the adjustments attributable to a sale. We generally base our estimates for the accrual of these items deducted from gross sales on historical experience and other relevant factors. We adjust our accruals periodically throughout each quarter based on actual experience and changes in other factors, if any.

We believe that our allowances and accruals for items that are deducted from gross revenue are reasonable and appropriate based on current facts and circumstances. However, it is possible that other parties applying reasonable judgment to the same facts and circumstances could develop different allowance and accrual amounts for items that are deducted from gross revenue. Additionally, changes in actual experience or changes in other qualitative factors could cause our allowances and accruals to fluctuate. A five percent change in the expenses related to the allowances and accruals described above would lead to an approximate \$5.9 million annual effect on our income before income tax expense, based on the amount of expense we recognized during the year ended June 30, 2005 (our most recent full fiscal year) related to the allowances and accruals described above.

**Table of Contents**

*Share-Based Compensation*

As part of our adoption of SFAS No. 123R as of July 1, 2005, we are required to recognize the fair value of share-based compensation awards as an expense. We apply the Black-Scholes option-pricing model in order to determine the fair value of stock options on the date of grant, and we apply judgment in estimating key assumptions that are important elements in the model such as the expected stock-price volatility, expected stock option life and expected forfeiture rates. Our estimates of these important assumptions are based on historical data and judgment regarding market trends and factors.

If actual results are not consistent with our assumptions and judgments used in estimating these factors, we may be required to record additional stock-based compensation expense or income tax expense, which could be material to our results of operations.

*Long-lived Assets*

We assess the impairment of long-lived assets when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Factors that we consider in deciding when to perform an impairment review include significant under-performance of a product line in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use of the assets. Recoverability of assets that will continue to be used in our operations is measured by comparing the carrying amount of the asset grouping to our estimate of the related total future net cash flows. If an asset carrying value is not recoverable through the related cash flows, the asset is considered to be impaired. The impairment is measured by the difference between the asset grouping's carrying amount and its fair value, based on the best information available, including market prices or discounted cash flow analysis.

When we determine that the useful lives of assets are shorter than we had originally estimated, and there are sufficient cash flows to support the carrying value of the assets, we accelerate the rate of amortization charges in order to fully amortize the assets over their new shorter useful lives.

*Income Taxes*

Income taxes are determined using an annual effective tax rate, which generally differs from the U.S. Federal statutory rate because of state and local income taxes, tax-exempt interest, charitable contribution deductions, nondeductible expenses and research and development tax credits available in the U.S. Our effective tax rate may be subject to fluctuations during the year as new information is obtained which may affect the assumptions we use to estimate our annual effective tax rate, including factors such as our mix of pre-tax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, reserves for tax audit issues and settlements, utilization of research and development tax credits and changes in tax laws in jurisdictions where we conduct operations. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities. We record valuation allowances against our deferred tax assets to reduce the net carrying value to an amount that management believes is more likely than not to be realized.

Based on the Company's historical pre-tax earnings, management believes it is more likely than not that the Company will realize the benefit of the existing net deferred tax assets at September 30, 2006. Management believes the existing net deductible temporary differences will reverse during periods in which the Company generates net taxable income; however, there can be no assurance that the Company will generate any earnings or any specific level of continuing earnings in future years. Certain tax planning or other strategies could be implemented, if necessary, to supplement income from operations to fully realize recorded tax benefits.

*Research and Development Costs and Accounting for Strategic Collaborations*

All research and development costs, including payments related to products under development and research consulting agreements, are expensed as incurred. We may continue to make non-refundable payments to third parties for new technologies and for research and development work that has been

**Table of Contents**

completed. These payments may be expensed at the time of payment depending on the nature of the payment made.

Our policy on accounting for costs of strategic collaborations determines the timing of our recognition of certain development costs. In addition, this policy determines whether the cost is classified as development expense or capitalized as an asset. We are required to form judgments with respect to the commercial status of such products in determining whether development costs meet the criteria for immediate expense or capitalization. For example, when we acquire certain products for which there is already an ANDA or NDA approval related directly to the product, and there is net realizable value based on projected sales for these products, we capitalize the amount paid as an intangible asset. In addition, if we acquire product rights which are in the development phase and to which we have no assurance that the third party will successfully complete its developmental milestones or that the product will gain regulatory approval, we expense such payments.

***Recent Accounting Pronouncements***

In June 2006, the FASB issued Interpretation No. 48 ( FIN 48 ) *Accounting for Uncertainty in Income Taxes*, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with FASB Statement No. 109, *Accounting for Income Taxes*. FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006. We are currently evaluating FIN 48 but do not expect it to have a material impact on our consolidated results of operations and financial condition.

In September 2006, the FASB issued SFAS No. 157, *Fair Value Measurements*, which clarifies the definition of fair value, establishes a framework for measuring fair value, and expands the disclosures about fair value measurements. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007. We are currently evaluating SFAS No. 157 and its impact, if any, on our consolidated results of operations and financial condition.

**Forward-Looking Statements**

This Quarterly Report on Form 10-Q and other documents we file with the SEC include forward-looking statements. These include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales and marketing efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. From time to time, we also may make forward-looking statements in press releases or written statements, or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls, and conference calls. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act ). These statements are based on certain assumptions made by us based on our experience and perception of historical trends, current conditions, expected future developments and other factors we believe are appropriate in the circumstances. We caution you that actual outcomes and results may differ materially from what is expressed, implied, or forecast by our forward-looking statements. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond our control. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as anticipate, estimate, expect, project, intend, plan, believe, will, should, outlook, could, target, and other words with similar meaning in connection with any discussion of future operations or financial performance. Among the factors that could cause actual results to differ materially from our forward-looking statements are the following:

- competitive developments affecting our products, such as the recent FDA approvals of ARTEFILL<sup>®</sup>, JUVEDERM<sup>®</sup>, HYLAFORM<sup>®</sup>, HYLAFORM PLUS<sup>®</sup> and CAPTIQUE<sup>®</sup>, competitors to RESTYLANE<sup>®</sup>, a generic form of our DYNACIN<sup>®</sup> Tablets product, generic forms of our LOPROX<sup>®</sup> TS and LOPROX<sup>®</sup>



**Table of Contents**

Cream products, and potential generic forms of our LOPROX<sup>®</sup> Shampoo, LOPROX<sup>®</sup> Gel, TRIAZ<sup>®</sup> or PLEXION<sup>®</sup> products;

the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved;

changes in the FDA's position on the safety or effectiveness of our products. For example, in the August 29, 2006 Federal Register, the FDA issued a notice of proposed rulemaking to categorically establish that over-the-counter skin bleaching drug products are not generally recognized as safe and effective and are misbranded. If the proposed rule is adopted, all manufacturers of skin bleaching products would be required to remove their products from the market and obtain FDA approval prior to re-entering the U.S. market. ESOTERICA<sup>®</sup> is an over-the-counter product line sold by the Company that contains bleaching products that would be regulated by the proposed rule and if that occurs the Company does not currently intend to invest in obtaining an approved NDA for this product line. This product accounted for \$1.5 million in net revenues during the nine months ended September 30, 2006;

changes in our product mix;

changes in prescription levels and the effect of economic changes in hurricane-affected areas;

manufacturing or supply interruptions;

importation of other dermal filler products;

changes in the prescribing or procedural practices of dermatologists, podiatrists and/or plastic surgeons;

the ability to successfully market both new and existing products;

difficulties or delays in manufacturing;

the ability to compete against generic and other branded products;

market acceptance of our products and negative reports and publicity regarding the efficacy, safety or side effects of dermal restorative products;

trends toward managed care and health care cost containment;

our ability to protect our patents and other intellectual property;

possible U.S. legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including Medicaid and Medicare and involuntary approval of prescription medicines for over-the-counter use;

legal defense costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent protection, government investigations, and other legal proceedings (see Part II, Item 1, Legal Proceedings);

changes in U.S. generally accepted accounting principles;

additional costs related to compliance with changing regulation of corporate governance and public financial disclosure;

any changes in business, political and economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world;

access to available and feasible financing on a timely basis;

**Table of Contents**

the risks and uncertainties normally incident to the pharmaceutical and medical device industries, including product liability claims;

the risks and uncertainties associated with obtaining necessary FDA approvals;

unexpected costs and expenses, or our ability to limit costs and expenses as our business continues to grow; and

the impact of acquisitions, divestitures and other significant corporate transactions.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to review any future disclosures contained in the reports that we file with the SEC. Our Transition Report on Form 10-K/T for the six-month period ended December 31, 2005 contains discussions of various risks relating to our business that could cause actual results to differ materially from expected and historical results, which is incorporated herein by reference and which you should review. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list or discussion to be a complete set of all potential risks or uncertainties.

**Table of Contents**

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

As of September 30, 2006, there were no material changes to the information previously reported under Item 7A in our Transition Report on Form 10-K/T for the six-month period ended December 31, 2005.

**Item 4. Controls and Procedures**

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) that are designed to ensure that information required to be disclosed in reports filed by us under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer, with the participation of other members of management, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2006 and have concluded that, as of such date, our disclosure controls and procedures were effective to ensure that the information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

Although the management of our Company, including the Chief Executive Officer and the Chief Financial Officer, believes that our disclosure controls and internal controls currently provide reasonable assurance that our desired control objectives have been met, management does not expect that our disclosure controls or internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

During the three months ended September 30, 2006, there was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**Table of Contents****Part II. Other Information**

## Item 1. Legal Proceedings

The government notified us on December 14, 2004, that it is investigating claims that we violated the federal False Claims Act in connection with the alleged off-label marketing and promotion of LOPROX® and LOPROX® TS products ( LOPROX® ) to pediatricians during periods prior to our May 2004 disposition of the Company's pediatric sales division. On or around October 5, 2006 the parties agreed in principle to resolve all federal and state civil claims against the Company for \$9.8 million. Accordingly, we have accrued a loss contingency of \$9.8 million as of September 30, 2006, related to this matter.

On or about October 12, 2006, the Company and the United States Attorney's Office for the District of Kansas entered into a Nonprosecution Agreement wherein the government agreed not to prosecute the Company for any alleged criminal violations relating to the alleged off-label marketing and promotion of LOPROX®. In exchange for the government's agreement not to pursue any criminal charges against the Company, the Company has agreed to continue cooperating with the government in its ongoing investigation into whether past and present employees and officers may have violated federal criminal law regarding off-label marketing and promotion of LOPROX® to pediatricians. No individuals have been designated as targets of the investigation. Any such claims, prosecutions or other proceedings, with respect to our past and present employees and officers, the cost of their defense and fines and penalties resulting therefrom could have a material impact on our reputation, business and financial condition.

The Company also is engaged in discussions with the Office of Inspector General of the Department of Health and Human Services ( IG ) to resolve any potential administrative claims the IG may have arising out of the government's investigation into the Company's marketing and promotion of LOPROX®.

On October 27, 2005, we filed suit against Upsher-Smith Laboratories, Inc. of Plymouth, Minnesota and against Prasco Laboratories of Cincinnati, Ohio for infringement of Patent No. 6,905,675 entitled Sulfur Containing Dermatological Compositions and Methods for Reducing Malodors in Dermatological Compositions covering our sodium sulfacetamide/sulfur technology. This intellectual property is related to our PLEXION® Cleanser product. The suit was filed in the U.S. District Court for the District of Arizona, and seeks an award of damages, as well as a preliminary and a permanent injunction. A hearing on our preliminary injunction motion was heard on March 8 and March 9, 2006. The Court did not grant the preliminary injunction, but the case continues and we are considering pursuing the matter. We have asked the U.S. Patent and Trademark Office to confirm the validity of this patent by way of a re-examination proceeding, which is expected to consider all of the prior art cited by the defendants in opposition to our preliminary injunction motion.

On June 22, 2006, Medcis and Sanofi-Aventis Deutschland GmbH filed suit against Paddock Laboratories, Inc. of Minneapolis, Minnesota for infringement of United States Patent No. 7,018,656 B2 (the 656 patent ) entitled Antimycotic Gel With High Active Substance Release. Sanofi-Aventis Deutschland GmbH is the owner by assignment of the 656 patent. This patent contains one or more claims that cover the composition of LOPROX® Gel (ciclopirox) 0.77%. The suit was filed in the United States District Court for the District of Minnesota, and seeks, *inter alia*, a permanent injunction prohibiting Paddock Laboratories, Inc. from engaging in any commercial manufacture, use, offer to sell or sale within the United States or importation into the United States, of any drug product that infringes this patent. Paddock's answer to our June 22, 2006 complaint is due on August 14, 2006, and discovery will begin shortly thereafter.

In addition to the matters discussed above, we and certain of our subsidiaries are parties to other actions and proceedings incident to our business, including litigation regarding our intellectual property, challenges to the enforceability or validity of our intellectual property and claims that our products infringe on the intellectual property rights of others. We record contingent liabilities resulting from claims against us when it is probable (as that word is defined in Statement of Financial Accounting Standards No. 5) that

**Table of Contents**

a liability has been incurred and the amount of the loss is reasonably estimable. We disclose material contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimating probable losses requires analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. In all of the cases noted where we are the defendant, we believe we have meritorious defenses to the claims in these actions and resolution of these matters will not have a material adverse effect on our business, financial condition, or results of operation; however, the results of the proceedings are uncertain, and there can be no assurance to that effect.

**Item 1A. Risk Factors**

There are no material changes from the risk factors previously disclosed in Part I of Item 1A in our Transition Report on Form 10-K/T for the six month period ended December 31, 2005.

**Table of Contents**

Item 6. Exhibits

Exhibit 12+	Computation of Ratios of Earnings to Fixed Charges
Exhibit 10.1+*	Office Sublease by and between Apex 7720 North Dobson, L.L.C., an Arizona limited liability company, and the Company, dated as of July 26, 2006
Exhibit 31.1+	Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2+	Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1+	Certification by the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

+ Filed herewith

\* Confidential portions omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 promulgated under the Securities and Exchange Act of 1934, as amended.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MEDICIS PHARMACEUTICAL  
CORPORATION**

Date: November 9, 2006

By: /s/ Jonah Shacknai  
Jonah Shacknai  
Chairman of the Board and Chief  
Executive Officer (Principal Executive  
Officer)

Date: November 9, 2006

By: /s/ Mark A. Prygocki, Sr.  
Mark A. Prygocki, Sr.  
Executive Vice President Chief  
Financial Officer and Treasurer  
(Principal Financial and Accounting  
Officer)